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Mesenchymal stem cells (MSCs) have been previously shown to enhance skin wound 
healing through paracrine secretion of soluble factors that regulate inflammation and 
promote angiogenesis and tissue regeneration. In this work, it was found that MSCs 
can secrete and deposit extracellular matrix (ECM) that are conducive for wound 
healing through promoting normal human epithelial keratinocyte (NHEK) 
proliferation and motility. MSCs were shown to deposit ECM material rich in type I 
and IV collagen (Col I, Col IV) that are important structural proteins for wound 
healing. MSCs were also able to regulate their ECM deposition profile when pre-
activated with wound healing-related cytokines. ECM produced by MSCs pre-
activated with TGF-β1 and TNF-α showed an increase in the ratio of type III collagen 
to type I collagen. This is characteristic of the ECM in early wound healing stages. 
ECM secreted by MSCs is shown to support proliferation of keratinocytes except that 
this proliferative effect can be suppressed when MSCs were exposed to TGF-β1. 
Under most conditions, the ECM secreted by MSCs (whether pre-activated or not) 
enhanced keratinocyte motility. This suggested that MSC deposited ECM have the 
capacity to accelerate NHEK movement while facilitating cell proliferation. When 
MSCs were co-cultured with keratinocytes in direct contact, there was deposition of 
dermal epidermal junction (DEJ) related ECM components that consists of type I, IV, 
VII collagen and laminin 3,3,2. These findings are suggestive of the supportive role 
of ECM produced by MSCs in wound healing.  
 
Stem cells are known to home to wound sites. One strategy to maximize MSC 
treatment efficacy is to directly transfer MSCs to the wound. A poly (DL-lactide-co-
glycolide)-type I collagen based nanofibrous electrospun scaffold was created to 
facilitate the transfer of MSCs. The construct was functionalized by blending five 
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biochemicals beneficial for wound healing: Vitamin C (Vit C), Hydrocortisone (H), 
Insulin (I),  3,3,5- triiodo-L-thyronine sodium (T3) and Epidermal Growth Factor 
(EGF). The scaffold was mechanically strong, biodegradable and release 
approximately 80% of its incorporated factors in 12 hours. All included factors were 
individually tested to confirm biological functions post-fabrication. The combined 
factors were able to increase the proliferation of skin cells (such as HDFs and 
NHEKs) and to maintain the stemness of NHEKs in culture. In order to facilitate in 
situ combination of the fabricated construct with treatment MSCs, a cell filtration 
system was devised and the MSC-scaffold composite created accelerated wound 
closure and improved wound granulation tissue formation and structure in a full-
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1.1 Background and Motivation 
Burn injuries to the skin caused by high power energies such as heat, electricity, 
radiation, radioactivity, friction or contact with chemicals are a serious public health 
problem. In 2008, the world health organization (WHO) recorded that out of 410, 000 
burn injuries in the United States of America (USA), around 10% required hospital 
care. The annual burden of burn wound management in the USA for children alone 
exceeded US$ 211 million. The WHO estimated 265 000 deaths annually due to 
burns with almost half occurring in South-East Asia [1]. In Singapore, the Burn 
Centre at the Singapore General Hospital admits an average of 161 patients per year 
between 2003 and 2005 and saw a mortality rate of 4.5% [2]. Survivors of burn 
injuries often had to face severe morbidities such as prolonged hospitalization, 
disfigurement and disability.  
 
Full thickness skin wounds are wounds that have lost the entire skin depth (epidermis 
and dermis) down to the subcutaneous fat layer. These wounds, when larger than 1 
cm in diameter do not heal on their own and require timely surgical intervention for 
good healing outcomes [3]. While there are a large variety of wound healing products 
in the market, the autologous spilt thickness skin graft (STSG) still remains as the 
current clinical gold standard for the treatment of full-thickness skin wounds [4]. 
However, problems such as limited donor site availability and the creation of 
additional wound sites in already ill patients limits the use of the STSG. Allogenic 
grafts from cadaveric skin on the other hand have problems of availability and bring 
along with them dangers of pathogen transmission. Allogenic grafts can also only 
serve as temporary coverings due to eventual immune rejection.  
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Tissue engineering poses as an attractive alternative for the treatment of full thickness 
skin wounds. Current tissue engineering products includes either the use of living 
skin cell constructs, or dermal templates that aims to vascularize and prepare the 
wound bed for later application of cultured epidermal autografts (CEA) after its 
standard 6-8 weeks ex vivo expansion (summarized in Chapter 2). However, living 
constructs require special transport and storage conditions while acellular dermal 
constructs have shown variable efficacy [4-6]. There still remains a need for skin 
grafts that are safe, efficacious and convenient to use [7].   
 
The hypotheses of this project are based on the following rationales:  
 Mesenchymal stem cells (MSCs) showed promising potential in the 
management of skin wounds (summarized in Chapter 2). Both pre-clinical 
and clinical trial data reported that MSC-treated wounds have a faster rate of 
closure, increased granulation tissue formation and better quality of repair. 
Most literature have attributed their efficacy to paracrine secretions from 
MSCs that modulates the wound's inflammatory status, stimulates 
angiogenesis and drive granulation tissue formation. Although mesenchymal 
cells are contributors of extracellular matrix (ECM) in tissue, very little is 
known about MSC's role in modulating the microenvironment of the ECM.  
 
 Mesenchymal stem cells preferentially home to wound sites in response to 
inflammation and hypoxia induced signals [8,9]. However, a large number of 
cells need to be systemically injected in MSC therapy as only a very small 
percentage of cells have been shown to home to injury sites. Topical injection 
of MSCs into the wound site [10] improved on the efficacy of MSC treatment 
and administration of MSCs in a hydrogel scaffold enabled administered 
MSCs to retain viability for a longer time [11]. This suggests that 
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administering MSC treatment using a tissue engineered support scaffold 
would help enhance treatment results.   
 
 Functionalizing scaffolds by incorporating cytokines helped improve the 
wound healing capacity of tissue engineered scaffolds [12,13]. Most current 
strategies incorporate only single or dual biomolecules into their system. 
Given the complexity of wound healing, it is possible that a combination of a 
few biomolecules would help manage the multiple aspects of the healing 
process. Incorporation of a variety of cytokines however raise concerns over 
whether cytokines of different chemical properties can be delivered together 
while maintaining the bioactivity of every component. As a result, complex 
systems that involves combining different scaffold components were 
developed [14]. The complexity of such systems however made it 
challenging for large scale production. A simplified delivery system that 
allows for the incorporation of multiple bioactive cytokines at the same time 
is highly desired.  
 
 Early surgical intervention was found to help reduce the length of 
hospitalization and mortality of burn patients [15]. It was also reported to 
facilitate tissue salvage along with less pain and better scar outcomes [16]. 
Hence, it would be ideal to have an in situ system where an off-the-shelf 





1.2 Hypothesis and objectives 
Two hypotheses are proposed:  
1) Mesenchymal stem cells secrete ECM that modulate the wound healing 
process. 
2) An in situ combination of MSCs with wound modulating cytokines will 
improve wound healing. 
  
The specific aims to address hypothesis 1 include:  
1. To assess how the quality of ECM produced by BM-MSCs was affected 
when BM-MSCs were subjected to pre-activation with various cytokines.  
2. To assess how the variation of ECM quality affects its bioactivity.  
3. To assess the interaction between BM-MSCs and normal human epithelial 
keratinocytes (NHEKs) when in direct contact culture. 
The specific aims to address hypothesis 2 include:  
1. To fabricate and characterize a biodegradable electrospun nanofibrous 
scaffold functionalized with cytokines. 
2. To devise a system for quick concentration of cells onto the nanofibrous 
scaffold.  
3. To evaluate the efficacy of the functionalized nanofibrous scaffold as a MSC 




1.3 Research strategy  
The research strategies to address the specific aims of hypothesis 1 are:  
 
Hypothesis 1, Aim 1: To assess how the quality of ECM produced by BM-MSCs was 
affected when BM-MSCs were subjected to pre-activation with various cytokines.  
BM-MSCs were pre-activated with TGF-β1 and TNF-α and the ECM 
produced were assayed for type I, III and IV collagens (Col I, Col III, Col IV) 
and fibronectin (FN) and quantified. The quality of these ECM were 
compared with those from human foreskin dermal fibroblasts (HDF).     
  
Hypothesis 1, Aim 2: To assess how the variation of ECM quality affects its 
bioactivity. 
The bioactivities of the ECMs on the proliferation and motility of NHEKs 
were studied. The produced ECMs were first decellularized to remove 
contributing factors from living MSCs. The proliferation and motility of 
NHEKs seeded on decellularized MSC cell deposited ECM was then studied. 
HDFs deposited ECM were used as a control.  
 
Hypothesis 1, Aim 3: To assess the interaction between BM-MSCs and normal 
human epithelial keratinocytes (NHEKs) when in direct contact culture. 
BM-MSCs and NHEKs were grown in direct co-culture. The ECM 
deposition profile was surveyed for Col I, Col IV, type VII collagen (Col VII) 
and laminin 3,3,2 (lam 3,3,2). ECM deposition profiles of co-cultures of 
NHEKs with HDFs and monocultures of BM-MSCs, HDFs and NHEKs were 





The research strategies to address the specific aims for hypothesis 2 is summarized in 
Fig. 1.  
 
Fig. 1 : A schematic illustration of the research strategy for Hypothesis 2. 
 
Explicitly, the research strategies to address the specific aims for hypothesis 2 are:   
Hypothesis 2, Aim 1: To fabricate and characterize a biodegradable electrospun 
nanofibrous scaffold functionalized with cytokines. 
A poly (DL-lactide-co-glycolide) (PLGA)-collagen composite scaffold 
produced by electrospinning. L-ascorbic acid phosphate magnesium salt (Vit 
C), hydrocortisone, insulin, 3,3,5-triiodo-L-thyronine sodium (T3) and 
epidermal growth factor (EGF) were added to the electrospinning solution. 
The physical and chemical properties of the scaffold in terms of morphology, 
diameter, mechanical strength, shrinkage and degradation properties and 
factor release profile of the fabricated scaffold was assessed. In vitro assays 
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to study the bioactivity of included factors and the scaffold's ability to 
influence NHEK and HDF proliferation as well as maintain NHEK 
"stemness" was also performed.  
 
Hypothesis 2, Aim 2: To devise a system for quick concentration of cells onto the 
nanofibrous scaffold. 
Filtration was tested as a potential method to concentrate BM-MSCs onto the 
fabricated electrospun tissue modulating construct. A hand-held system to 
enable the filtration of cells was designed and fabricated using three-
dimensional (3D) printing.  
 
Hypothesis 2, Aim 3: To evaluate the efficacy of the functionalized nanofibrous 
scaffold as a MSC delivery system in an animal model. 
In a pilot study, BM-MSCs were combined with the composite scaffold 
fabricated in hypothesis 2, aim 1 and introduced into a splinted full-thickness 
skin wound for 15 days in order to assess the potency of the composite 
construct in modulating tissue regeneration. Wound closure kinetics, 














2.1 The Skin -- Its functions and structure 
The skin is a the largest organ in the human body and serves as a barrier between the 
body and the external environment, protecting the body from dehydration, infection 
and mechanical, chemical and thermal stress. It also houses a large number of sensory 
neurons with receptors for touch, pressure, pain and temperature and functions as a 
thermoregulator of the body by allowing dissipation of internal heat through 
perspiration. The skin also supplements metabolic functions of the body through 
synthesis of Vitamin D in the epidermis and making available triglycerides from the 
subcutaneous stores of adipose tissue [17].  
 
 
Fig. 2: Structure of the human skin. Reprinted by permission from Macmillan Publishers Ltd: 
[Nature, http://www.nature.com/] [18], copyright (2007). 
 
The skin is made of three main portions, the epidermis, the dermal-epidermal junction 




2.1.1 The Epidermis 
The epidermis has a thickness of 0.1-0.2 mm and is composed of 4-5 layers of 
keratinocytes interspersed with melanocytes, Langerhans’ cells and Merkel cells.  
Keratinocytes form the bulk of the epidermis and are classified in 4 layers: (in 
ascending order from deep to superficial) stratum basale, stratum spinosum, stratum 
granulosum and stratum corneum [18,19]. The stratum basale comprises of a high 
density of proliferating kertinocyte stem cells (basal cells) that are attached to the 
dermal-epidermal junction. These cells divide frequently and displaces older cells 
upwards as they do so. As the cells differentiate and migrates superficially into the 
stratum spinosum, keratinocytes lose their nuclei and undergo apoptosis. Leaving 
behind a layer of anucleated corneocytes and an extracellular lipid enriched matrix 
consisting of proteins such as involucrin and loricrin cross-linked by transgluaminase 
and cytoplasmic keratin filaments aggregated into macrofibrils by filaggrin.  The 
epidermis has no blood supply and receives nutrients via diffusion from the 
underlying dermal capillary network.  
 
Fig. 3: The structure of the epidermis. Reprinted from Goldman's Cecil Medicine, Vol 2, 
David A. Norris, Structure and Function of Skin, 2498-2503, Copyright (2012), with 
permission from Elsevier (http://www.elsevier.com). [20] 
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Melanocytes are melanin pigment producing dendritic cells located in the basal layer 
of the epidermis. They are found at a frequency of 1 in every 5 to 10 basal cells and 
provides the skin with photo and thermoprotection, helping to reduce the chance of  
skin cancer [21] . Langerhans cells are found amongst the stratum spinosum of the 
epidermis and are dendritic cells of mesenchymal origins. They play a key role in the 
adaptive immune response of the skin and are antigen-presenting cells [22]. Merkel 
cells on the other hand are probably derived from keratinocytes and are usually found 
in the stratum basale and the rete ridges of the skin, Merkel cells are associated with 
nerve endings and serve as mechanosensory receptors to touch [23].  
 
2.1.2 The Dermal-Epidermal Junction (DEJ) 
The DEJ is a complex basement membrane structure that zips the epidermis layer to 
the underlying dermis. It serves as a mechanical support for the epidermis. The DEJ's 
dense extracellular matrix content also serves as a barrier to the exchange of cells and 
large molecules across the junction. Components of the DEJ are made by both 
keratinocytes and fibroblasts [24].  
 
The DEJ consists of 4 zones:  
1) The plasma membrane of basal keratinocytes where the internal keratin 
intermediate filaments of basal keratinocytes are connected to the external 
environment via hemidesmosomes. Hemidesmosome then form the hemidesmosome 
adhesion complex with anchoring filaments (lam 3,3,2) and anchoring fibrils (Col 
VII) to bind basal keratinocytes to the basement membrane. Integrin α6β4 is a major 
active component of hemidesmosomes that binds to lam 3,3,2 [25].  
 
2) The lamina lucida made up mainly of lam 3,3,2, previously known as laminin V 
[26]. The cruciform structure of lam 3,3,2 allows it to bind to integrin α6β4 and Col 
VII on two separate ends, joining the epidermis to the dermis [27].  
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3) The lamina densa (basal lamina) that consist mainly of Col IV. There are six forms 
of Col IV but the main form is a fibrous collagen made up of 2 α1(IV) and 1 α2(IV) 
chains. Its non-collagenous (NC) terminals (NC-1) are capable of forming dimers and 
tetramers that becomes a lattice like sheet structure. Col IV binds to laminin 3,3,2 
through nidogen [28,29]. 
 
4) Anchoring fibrils, the dermal portion of the hemidesmosome adhesion complex 
that consists of mainly Col VII. Individual molecules of Col VII are approximately 
450 nm long, consisting of a triple helical central segment and NC globular domains 
at each end. Multiple type VII molecules aggregate to form bundles and their NC 
domains bind onto lam 3,3,2 while the helical portions loop into the dermis, trapping 




Fig. 4 Schematic diagram of molecules involved in the dermal-epidermal junction. Reprinted 
by permission from Macmillan Publishers Ltd: [Journal of Investigative Dermatology, 
http://www.nature.com/jid/index.html] [32], copyright (2008). 
 
2.1.3 The Dermis 
The dermis houses the hair follicles, lymphatic vessels, sebaceous, apocrine and 
sweat glands. It also contains nervous receptors for touch, temperature and pain. 
Functionally, it serves as a shock absorber for the skin and regulates the structure of 
the skin through dermal-epidermal interactions with the epidermis.  
 
The cells of the dermis are of mesodermal origin (with exception of nerves). Its ECM 
consists of a rich extracellular matrix (ECM) make-up involving mainly type I, III 
and V collagens bulk with an elastic fiber network and interlaced with proteoglycans 
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and glycoaminoglycans (GAG). Collagens provide the dermis with its bulk structural 
support while elastic fibers give skin its resilience and elasticity. Proteoglycans and 
GAGs on the other hand helps to contribute to the organization and architecture of the 
skin. They also bind to a large variety of cytokines and growth factors and can 
function to sequester or enhance the function of these molecules. For example, basic 
fibroblast growth factor (bFGF) bound to heparan sulfate proteoglycan, are protected 
from plasmin degradation but the binding sequestered its mitogenic activity [33]. 
Other growth factors that are bound to the ECM includes Granulocyte macrophage 
colony-stimulating factor (GM-CSF) [34], Vascular endothelial growth factor  
(VEGF) [35] and TGF-β1 [36].  
 
The dermis is subdivided into two layers, the upper papillary dermis and the lower 
reticular dermis. The papillary dermis is comprised of loosely arranged fibers and is 
reported to be important for dermal-epidermal interaction and the formation of hair 
follicles. The reticular dermis on the other hand have a denser collagen network and 
is important for the synthesis of the fibrillar ECM [37].  
 
Interspersed within the ECM of the skin are fibroblast cells that are the main 
producers of dermal collagens, elastin, mucopolysaccharides, chondroitin sulfate and 
glycoproteins. Dermal fibroblasts also excrete many cytokines and growth factors, 
such as keratinocyte growth factor (KGF) and GM-CSF that are stored in the rich 
ECM reservoir of the skin. The multiple secretions of the dermal fibroblast mediates 
epidermal proliferation and differentiation to mediate maintenance of the skin's 
integrity and repair during an injury [38].  
 
2.2 Dermal Epidermal Crosstalk  
The crosstalk between epidermal keratinocytes and dermal fibroblasts is essential for 
proper structure and function of the skin. Keratinocytes secrete cytokines such as 
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TGF-β1 that can influence fibroblast proliferation and collagen secretion [39]. 
Fibroblasts on the other hand secrete KGF and heparin-binding epidermal growth 
factor (HB-EGF) that will increase keratinocyte proliferation and migration [40].  
 
The DEJ is an expression of the crosstalk between the epithelial keratinocyte and the 
dermal mesodermal fibroblasts. It is extremely important in maintaining the 
mechanical integrity of the skin. However, in wound site, the DEJ does not get 
formed until complete reepithelialization of the wound area is established [41]. This 
suggests that direct dermal epidermal crosstalk is important in the establishment of a 
DEJ. Conditioned media from keratinocyte or fibroblast monocultures were reported 
to not be able to simulate the expression of a basement membrane components such 
as Col IV, Col VII, Lam 3,3,2 and nidogen at their respective location as well as 
conditioned media from the co-culture of keratinocytes with fibroblasts. Morover, 
conditioned media alone do not seem to be sufficient to induce proper DEJ structure, 
indicating that other crosstalk mechanisms such as direct cell-cell contact may be in 
play [42]. Smola et al. showed that it is only when keratinocytes are allowed to have 
direct contact with dermal fibroblasts in organotypic culture, that a structurally well 
defined epidermis is formed in-vitro [43]. Marionnet et al. also reported that 
keratinocytes are essential for the preferential localization of all proteins synthesized 
by fibroblasts at the DEJ. Fibroblast close proximity is essential for the correct 
deposition of Col VII and Lam 3,3,2 by keratinocytes. In the absence of 
mesenchymal cells, proteins were completely or partially retained within 
keratinocytes [44]. The full spectrum of growth factors that's involved in dermal-
epidermal interaction have not been defined, but to date, some of the factors found to 






Table 1: Factors involved in dermal epidermal crosstalk and their effect on skin wound repair. 
Growth factor Source Effect on skin cells Reference 
Keratinocyte 
growth factor 
(KGF or FGF 7) 
Fibroblasts Increase keratinocyte proliferation. [47,48] 




Fibroblasts Increase angiogenesis, accelerate 







Induce granulation tissue formation, 
stimulate keratinocyte proliferation, 
mediate Langerhan cell maturation 
(related to inflammatory respond), 





Chemoattractant of fibroblasts, 
monocyte/macrophages, modulates 
angiogenesis, increase fibroblast 
proliferation, increase fibroblast 
collagen secretion, increase fibroblast 
to myofibroblast transformation.  
[54-56] 
HB-EGF Fibroblasts  Increase keratinocyte and fibroblast 
proliferation. Accelerate keratinocyte 
migration, induce type VII collagen 






Keratinocytes Autocrine stimulation of keratinocyte 
proliferation, strong mitogen for 
fibroblasts, stimulate laminin 3,3,2 








Increase proliferation and migration of 
both fibroblasts and keratinocytes, 
stimulate production of collagen and 








First released by degranulating 








Increase proliferation of fibroblasts but 
not keratinocytes. Pro-inflammatory in 
nature, induces the secretion of other 








2.3 Skin Wounds -- Classification 
Skin wounds can be broadly classified according to the depth of tissue lost. The 
deepness classification will determine its treatment/management. When only part of 
the epidermis is lost, it is termed a superficial wound and will heal on its own with 
only supportive treatment given. Healing occurs rapidly by regeneration from 




When the wound gets deeper to include the papillary dermis, the wound is defined as 
a superficial partial thickness burn and involves the loss of the epidermis, the 
underlying basement membrane and the superficial papillary portion of the dermis. 
Even though the wound would usually heal within a week through regeneration, delay 
will occur should the wound progress deeper. Antimicrobial creams and occlusive 
dressings are used to aid re-epithelialization in a moist environment [78].  
 
Intermediate partial thickness wounds involve more dermal damage and irreversible 
denaturation of collagen. The repair process by fibroblasts will fill up the defect but 
the re-deposited collagen would have a looser orientation and lower mechanical 
strength that are manifested as scars. The gold standard of treatment of intermediate 
wounds remains to be the allogenic cadaveric skin. In cases when the application of 
allogenic dressing is not feasible, occlusive biologic (porcine derived) dressing and/or 
adherent non-biologic dressings such as Aquacel [79], are used. Deeper intermediate 
wounds may require debriding by tangential shaving. 
 
Deep partial-thickness and full thickness wounds on the other hand requires debriding 
or fascial excision. A spilt thickness autograft is the gold standard in the treatment of 
such wounds. If the wound is small, a sheet autograft would be the preferred option 
due to its ability to heal with the least contracture and morbidity. If the damaged area 
gets too large, the autograft will be meshed into a net in order to have sufficient 
material to cover larger areas. Even so, a mesh ratio no larger than 1:3 was reported 
to be preferred. An allogenic skin graft will then be used as a protective and biologic 
dressing in a "sandwich" method [80]. Autologous skin grafts are usually harvested 
from the thigh, legs, back and abdomen of the patient. When autograft sources are 
insufficient due to large burn areas, skin biopsies will be taken and cultured for 2-6 
weeks ex-vivo to yield a thin autologous keratinocyte sheet. The patient will be 
treated with temporary allogenic dressings or dermal templates in the meantime.  
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Nevertheless, while allogenic and autogenic grafts remain the gold standard in the 
treatment of burn wounds, their limited availability and risk of contamination and 
disease transmission call for the development of tissue engineered skin grafts.  
 
2.4 Wound healing -- with focus on cytokines and extracellular matrix (ECM) 
Wound healing is a highly orchestrated event in which each stage is highly dependent 
on the previous for initiation and the next for termination [81]. Any upset of the 
balance will result in either non-healing chronic wounds or hypertrophic scarring on 
the two ends of the spectrum. Wound healing can be broadly characterized into four 
phases: Hemostasis, Inflammation, Proliferation and Remodelling.   
 
2.4.1 Hemostasis 
Hemostasis is the first response of the wound to curb any insults. The aim of this step 
is to form a clot in order to limit blood loss and prevent pathogen entry. The clot later 
serves as a network for incoming inflammatory cells and is a reservoir of cytokines 
and growth factors [82].  
 
Following disruption of vessel walls (for 5-10 minutes post-injury), vasoconstriction 
occurs as a local response of blood vessels to limit blood loss and slows down blood 
flow to the local region [83]. The exposed collagens of the vessel walls then triggers 
adherence and activation of platelets to release thrombin. Thrombin is a serine 
protease that cleaves soluble fibrinogen to insoluble fibrin that forms the bulk of the 
clot. Other components of the clot includes fibronectin, vitronectin, trombospondin, 
erythrocyte and platelets [84]. Thrombin also functions as a vasodialator to increase 
plasma extravasation, allowing the entry of inflammatory cells attracted by platelet 
secreted TGF-β1, PDGF and VEGF and endothelial cell released pro-inflammatory 





Fig. 5: Schematic diagram of growth factors involved in the initial stages of wound healing. 
Reprinted by permission from Macmillan Publishers Ltd: [Journal of Investigative 
Dermatology, http://www.nature.com/jid/index.html] [86], copyright (2007). 
 
2.4.2 Inflammatory phase 
The first inflammatory cells that enter the wound are neutrophils (24-36 hour post 
wounding) that phagocytose invading bacteria. Neutrophils release reactive oxygen 
species, eicosanoids, proteolytic enzymes like elastase, cathepsin G, urokinase-type 
plasminogen activator that debrides the wound of foreign materials. Neutrophils also 
release cytokines such as TNF-α, IL-1β, IL-6, VEGF and IL-8 to further recruit 
monocytes into the wound [83]. Unless further stimulated, neutrophils are eliminated 
by phagocytosis by incoming macrophages or apoptotic cell death [81].   
 
Monocytes typically appear in the wound 48-72 hours after wounding, attracted by 
clotting factors, complement components and cytokines such as PDGF, TGF-β, 
leukotriene 134 and platelet factor IV. Upon activation by inflammatory cytokines 
such as lipopolysaccharide (LPS), TNF-α and interferon-γ (IFN-γ), monocytes 
differentiate into macrophages (or otherwise known as classically activated 
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macrophages, M1) [87]. M1 macrophages have high microbicical abilities and secrete 
high levels of proinflammatory cytokines and mediators such as TNF-α, and IL-6. 
They also produce large amounts of superoxide anions and oxygen and nitrogen 
radicals such as NO and citruline to kill microbes. They also present antigens to T 
lymphocytes and promote IL-12 mediated T-helper cell (Th)-1 response [88] and 
helps to attract dendritic cells and natural killer cells into the wound. M1 
macrophages needs to be curbs as prolonged M1 activation will leave to tissue 
damage.   
 
M2 macrophages or alternatively activated macrophages are a collective spectrum of 
macrophages that can be widely defined as two forms of macrophages:  
1) Wound healing macrophages that are activated by the presence of IL-4 and IL-13. 
IL-4 stimulation of macrophages results in increased arginase activity in macrophages 
that facilitates the conversion of arginine to ornithine, a precursor of polyamine and 
collagen, contributing to ECM production in the wound. Wound healing macrophages 
also have an indirect immunoregulatory effect as polyamines influence the production 
of cytokines such as IGF-1 and suppresses the clonal expansion of lymphocytes.  
2) Regulatory macrophages that are activated by TGF-β, IL-10 and  glucocorticoids. 
They serve to suppress inflammatory reaction and adaptive immune response while 
stimulating angiogenesis and signal for proliferation of fibroblasts, keratinocytes and 
endothelial cells. M2 macrophages secrete high levels of immunosuppressive IL-10 
that stimulate Th-2 cell response. [89] 
 
2.4.3 Proliferation phase 






This stage occurs around 24 hours after wounding and involves the movement of 
keratinocytes from the wound edges and hair follicles (if they are still around) 
into the wound. Massive cell proliferation that peaks 1-2 days post-wounding 
occurs in cells 300-400 cells away from the wound edge stimulated by EGF-
receptor ligands such as EGF, TGF-α, KGF and HB-EGF[90].  TNF-α also 
activates the anti apoptotic gene Akt in keratinocytes [91]. Keratinocytes at the 
wound edges then are activated to move by the lost of cell-cell contact and wound 
cytokines such as EGF, KGF, IGF-1 and nerve growth factor (NGF). Migrating 
keratinocytes are stimulated by the presence of EGF, TGF-α and TGF-β present 
at high levels in the provisional matrix formed during inflammation phase. They 
replace cytokeratin 1 (K1) and K10 suprabasal cytokeratin filaments for flexible 
cytokeratins, K6 and K16. The cells then flattens and elongates and moves using 
lamellipodia with integrins α5β1, α3,β1 and αvβ5 [81]. In order to create a path 
through the fibrin clot, keratinocytes produce large amounts of metalloproteinases 
(MMPs) and urokinase-type plasminogen activator that degrades basement 
membrane, collagens and fibrinogen to allow the cells to migrate competitively 
along a chemotatic gradient established by IL-1 [41,92] until a continuous 
undisrupted layer of keratinocytes is formed. 7-9 days after the completion of 
wound reepithelialization, the basement membrane zone then loses its fibronectin 
and fibrinogen components and redeposition of Col IV and laminin [41]. At this 
stage, the a straight line of integrin α6β4 expression can be found at the dermal 
epidermal junction indicating complete establishment of the dermal epidermal 
connection [93].   
 
2) Angiogenesis 
Neovascularization is stimulated by day 2 post-wounding by angiogenic factors 
such as VEGF, PDGF, FGF, TGF-β and thrombin secreted by platelets, 
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macrophages, keratinocytes and fibroblasts. Similar to migrating keratinocytes, 
endothelial cells secrete proteolytic MMPs to dissolve the vascular basement 
membranes and migrate with the use of superficial adhesion molecules adhesion 
molecules integrin αvβ3, αvβ5 and α5β1 [94].  
 
3) Granulation Tissue Formation 
Granulation tissue formation replaces the blood clot's fibrin/fibrinogen 
provisional matrix towards the end of the proliferation phase. During this time, 
fibroblasts migrate into the blood clot and under the stimulation of cytokines 
from the TGF-β family, IGF-1, PDGF, connective tissue growth factor (CTGF) 
and hypoxia-induced shock protein [95-97]. Fibroblasts that enter the wound 
during early granulation tissue formation proliferates massively and gets 
transformed into wound myofibroblasts. Their transformation is induced by 
primarily TGF-β1 but can also involve IL-6, CTGF, PDGF and mechanical stress 
[98,99]. Myofibroblasts contribute to wound contraction that is necessary to 
reduce the wound area and are major contributors to the extracellular matrix. 
They are then preferentially eliminated from the wound site by apoptosis during 
the later stages of wound healing. Prolonged presence of myofibroblasts in 
wound sites have been referred as the source for keloid formation and excessive 
scarring.  
 
2.4.4 Remodelling Phase 
The remodelling phase takes place from around day 21 post-wounding and may last 
for as long as two years. During this stage, remodelling of the deposited granulation 
tissue takes place to form long term scar matrices. Col III can make up of as much as 
40% of the ECM in a granulation tissue (unwounded skin have around 25% Col III). 
During this stage, Col III is replaced by Col I and the ECM is rearranged to form 
parallel bundles distinct of scar tissue as opposed to the basket-weave appearance of 
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normal skin [100]. This remodelling is caused by a range of proteases and protease 
inhibitors such as plasmin, MMPs, hyaluronidase, elastase, tissue inhibitor of 
metalloproteinases (TIMPs) and syndecans [90]. A balance of cytokines such as IL-6, 
TGF-β, IL-10, and bFGF secreted by macrophages and T-lymphocytes (Th-1 
population) regulates this process [85]. Towards the of phase, apoptosis of the 
fibroblasts, endothelial cells, macrophages etc occurs, leaving behind a scar that is 
avascular and acellular [83].  
 
2.5 Tissue Engineered Wound Healing Solutions 
A wide spectrum of tissue engineered wound dressing solutions have be developed to 
date. They are largely based on the traditional tissue engineering paradigm as 
illustrated in Fig 6 [86]. The tissue engineered construct starts with a scaffold made of 
a polymer material. The polymer can be biological (such as collagen or silk) or 
synthetic (such as poly-ε-caprolectone (PCL) or poly-ᴸ-lactic acid (PLLA)) . In 
acellular constructs, the polymeric construct can be functionalized by the addition of 
ligands such as growth factors or cytokines. In cellular constructs, cells (autologous 
or allogenic) wound be seeded onto the scaffold and allowed 2-4 weeks for the cells 





Fig. 6: The basic building blocks of a tissue-engineered construct. Reprinted by permission 
from Macmillan Publishers Ltd: [Journal of Investigative Dermatology, 
http://www.nature.com/jid/index.html] [86], copyright (2007). 
 
2.6 Commercially available TE constructs 
The wound repair systems are mainly categorized into three groups, the epidermal 
coverings, the dermal replacement templates and the dermal-epidermal skin 
equivalents (composite substitutes). A brief summary with a couple of examples will 
be discussed here [102].    
 
2.6.1 Epidermal covering 
Epidermal coverings contain only autogenic keratinocytes. They are either grown as a 
cell sheet as in EpiCel from Biosurface Technologies (that later got acquired by 
Genzyme Tissue Repair (Cambridge, MA, USA)) [103,104] or manifest as cell sprays 
such as that of ReCell from Avita Medical (Cambridge, United Kingdom) or 
CellSpray from Clinical Cell Culture (Perth, Australia). Their production requires a 
skin biopsy from the patient and the extracted skin is processed to isolate 
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keratinocytes that are either cultured in vitro or reapplied immediately onto the 
wound surface. In the case of EpiCel, the cells were grown in vitro for a period of 2-6 
weeks prior to re-implantation into the patient. The indications of the product is for 
deep dermal or full thickness wounds and aim to provide an epidermal covering while 
the deeper dermal layer repairs. Unfortunately, the long waiting time for the 
epidermal grafts makes it not so useful for acute wounds that require rapid coverage. 
The grafts are also frail and require complicated handling and application procedures 
[102]. Nevertheless, there have been report of unsatisfactory response in deep burns 
and full thickness wounds due to the lack of dermal component and its susceptibility 
to contractures [105]. Spray on products such as Recell on the other hand aims to 
treat more superficial partial thickness wounds or supplement spilt thickness mesh 
grafts. They do not require pre-expansion and allows immediate application on the 
patient, however, its usage is limited to partial thickness wounds.  
 
2.6.2 Dermal replacement 
A well vascularized dermal wound bed will greatly improve the take of epidermal 
grafts [106]. Dermal constructs can be acellular made of materials from allogenic or 
xenogenic origin or cellular, containing allogenic fibroblasts. They have less batch to 
batch variability than autologous epidermal grafts but will require a permanent 
epidermal substitute to work effectively. Alloderm (LifeCell Corporation, Banchburg, 
NJ, USA) is a permanent decellularized lyophilized cadaveric dermis with a 
preserved basement membrane. However, the thickness of the graft makes it more 
difficult for vascularization to occur. The product is more preferentially used in 
reconstructive surgeries that require less vascularization such as abdominal wall 
hernia reconstruction. Permacol (Tissue Science Laboratories plc, Aldershot, UK) is a 




One of the most popular dermal template in the market is Integra that was developed 
by Yannas & Burke [107]. It consists of a collagen and chondroitin-6-sulfate based 
dermal template covered with an outer silicone covering that functions as a protective 
layer to keep the wound moist while allowing the development and maturation of the 
granulation tissue. The template was designed to recruit dermal fibroblasts and be 
eventually degraded and replaced with autologous generated extracellular matrix. The 
outer silicone covering prevents epithelialization and is removed after the dermal bed 
is well vascularized (usually 2-3 weeks after placement) before application of a spilt 
thickness skin graft. It is probably the most successful tissue engineered dermal 
substitute to date but some of its disadvantages includes the need for a well prepared 
sterile wound bed to ensure good "take" of Integra and the need for a second 
operative procedure with a spilt thickness skin graft to achieve permanent closure.  
 
Transcyte (Advanced BioHealing, CT, USA) on the other hand contains human 
neonatal fibroblasts seeded on a nylon mesh that is bonded to porcine dermal 
collagen. As the construct is frozen prior to packaging, it is free of cellular metabolic 
activity and is only a tissue matrix with bound growth factors. It serves as a 
temporary wound dressing to enhance dermal reconstruction for partial-thickness 
burn wounds and donor sites treatment or as a dressing over meshed autografts until 
permanent closure is achieved.  
 
Lastly, Dermagraft (Advanced BioHealing) is a living construct with human neonatal 
fibroblasts seeded on a biodegradable/bioabsorbable PLGA scaffold. Dermagraft is 
US Food and Drug Administration  (FDA) approved to treat diabetic foot ulcers and 
was designed to facilitate normal wound healing through the secretion of factors such 
as IL-6, IL-8 and TGF-β and allow the creation of a viable wound bed for 




2.6.3 Dermal-epidermal skin equivalents (composite substitutes) 
Composite skin substitutes aim to mimic the natural anatomy of the skin and are the 
most sophisticated skin substitute product. Apligraft developed by Organogenesis Inc. 
(Canton, Massachusetts, CA, USA) is derived by seeding allogenic keratinocytes on 
top of a bovine collagen I gel pre-seeded with allogenic neonatal fibroblast [109]. 
However, the product has only been approved by FDA for treatment of venous leg 
ulcers and chronic leg ulcers. As skin substitutes, Apligraft was reported to carry a 
risk of graft rejection and disease transfer and serve only as temporary dressings for 
delivery growth factors and ECM [110].  
 
OrCel which is approved for the treatment of donor sites and treatment of patients 
with epidermolysis bullosa is a bilayer tissue engineered product. Each side of the 
collagen gel in this product was seeded with either keratinocytes or fibroblast from 
the same neonatal foreskin. It exerts its influence through the secretion of 
biomolecules before its allogenic origin causes it to be rejected from the wound in 7-
14 days. The biggest bottleneck of composite substitutes is their high cost of 
production and the difficulty of maintaining and transporting them (Apligraft for 
example have a shelf-life of only 5 days) [5]. 
 
2.7 The clinical unmet need  
In view of the shortcomings of the individual systems described above, there remains 
a need for an easily applicable and cost-effective alternative. The ideal skin substitute 
should have the following properties:  
 
1) Be biodegradable so no further surgery or procedures would be necessary to 
remove the construct on a later date 
2) Be bioactive, conferring the construct not only ability to support the growth 
of cells, but also to positively influence the wound site 
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3) Have adequate mechanical strength for easy handling by surgeons 
4) Be easily sterilizable  
5) Have a practical shelf life and does not require special transport and storage 
temperatures.  
 
2.8 Electrospinning in skin tissue engineering 
There are many research effort to fabricate the ideal scaffold for skin regeneration. 
Some of the techniques involve the use of phase separation[111], self-assembly 
[112,113], three-dimensional printing [114]etc. Amongst them, electrospinning is one 
of the most versatile technique.  
 
Electrospinning is a highly robust way of creating tissue engineered dressings. The 
fundamental set-up of electrospinning is shown in Fig. 7. It consists of 3 main 
components: 1) a syringe-pump connected to a syringe with a flat tipped needle 
(spinneret), 2) a high voltage electric source and 3) a grounded collector.  
 
 





The polymer(s) of choice would be first be dissolved in a conductive solvent such as 
dichloromethane (DCM) or 1,1,1,3,3,3-hexafluoro-2-propanol (HFP). The polymer 
solution is then mixed until homogenous and fed into the spinneret at a 
fixed/optimized feed-rate. The needle of the spinneret is connected to a high voltage 
generator (typically at ± 5 to 30 kV) that charges the polymer solution up, creating a 
force from the polymer solution towards the grounded. When the voltage exceeds a 
critical value, the polymer solution overcomes its surface tension and is pulled 
towards the collector, forming a conical shaped Taylor cone that pulls into finely 
charged jet from the tip. The jet then pulls into one continuous ultrathin fiber that is 
collected on the grounded collector. The collector can have different forms such as a 
flat plate, disc or cylinder that would in turn form fibers of different organization. 
Generally, static collector plates results in randomly aligned fibers while using 
rotating cylindrical collectors would cause the fibers to be aligned into a desired 
patterned [115]. 
 
Electrospinning can be used to create both micro or nanoscale sized fibers. Fiber 
membranes have many attractive physical properties as a skin dressing including:  
1) a nanostructured surface that facilitates cell adhesion and proliferation  
2) a high porosity that prevents fluid accumulation and allows gaseous exchange 
within the highly metabolically active wound site 
3) an infrastructure that mimics the natural collagen extracellular matrix [86,101]. 
 
A large range of polymers can be electrospun. Additional function can be introduced 
into the constructs by adding chemicals, nanoparticles or biomolecules. Table 2 
summarizes the ways to functionalize electrospun scaffolds. Manufacturing of 
electrospun nanofibers can be done under GMP conditions and is scalable with 




Table 2: Techniques to functionalize electrospun scaffolds. [117,118] 
Technique Fiber schematics Advantages Disadvantages 
Blending  
 




- burst release 












  Set-up          Fiber schematics 
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- long lasting 
due to chemical 
cross-linking 
- troublesome to 
manufacture 
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There are a number of works that functionalized their electrospun constructs for skin 



















via PEG linkers 
In vitro and in vivo (diabetic rat)  
Increased wound healing 
[119] 
PCL-PEG  DNA Chemical 
attachment via 
MMP-cleavable 
peptide link  
In vitro and in vivo (diabetic rat) 
More efficient transfection ratio then 
naked DNA or incorporated matrix.  
[120] 
PLGA Ibuprofen  Blend 
electrospinning 
In vitro studies 
Rapid release in the first 8 hours then 
slower release later. Addition of 
ibuprofen did not affect fibroblast 
attachment and proliferation and 
significantly reduced the response of 







In vitro studies 
Drug release evaluations that showed 
varying degree of swelling, weight 
loss, initial burst tnad rate of drug 
release depending on kind of polymer 




Chitosan  Coating In vitro studies 
Increased hemostatic activity with 








In vitro studies 





bFGF and EGF Coaxial spun 
bFGF and EGF 
chemically 
conjugated 
In vitro and in vivo(diabetic mice)  
Binary release profile with high initial 
burst of bFGF and slow release of 
EGF. Histological examination showed 
increased collagen accumulation and a 
cemented matrix of keratin.  
[13] 
PEG/PLA bFGF Core-sheath, 
emulsion 
In vitro and in vivo (diabetic rats) 
Enhanced cell adhesion, proliferation 
and secretion of extracellular matrix in 
vitro.  
Higher wound recovery rate than free 
bFGF, regeneration of skin 
appendages, higher density and mature 
capillary vessels, enhanced vcollagen 
deposition and ECM remodelling and 










In vitro studies 
Reduced burst release when core-shell 
electrospinning was used. Encapsulated 
core-shell fibers increased proliferation 
of adipose derived stem cells (ADSC) 
with a higher percentage differentiating 











In vitro studies 
Antibacterial properties with ZnO 
when tested with E. coli and S. aureus. 
Cell adhesion potential tested with 
L929 cells.  
[126] 
Silk and PEO EGF Blend 
electrospinning 
In vitro skin wound model 
Increased epithelial tongue closure in 






In vitro and in vivo mouse model 
No influence on the pharmacological 
activity of the drug in vitro selective 
inhibition of T cell function while not 
suppressing activity of stimulated 
macrophages. In vivo covering of 
wound in mouse attenuated local 







In vitro studies 
Early spreading and differentiation of 
seeded human dermal keratinocytes 
(HS2) with statistically high expression 






In vitro studies 
L929 cells showed early cell spreading 









In vivo studies (full thickness in nude 
mice) 
Increased Ki067 expression 
(proliferative marker), increased CD31 











In vitro and in vivo studies 
Faster complete re-epithelialization of 
wounds with greater inhibition of scar 
formation assessed via scar elevation 
index (SEI), lower collagen type I  
accumulation.  
[132] 




In vitro studies 
Positive human dermal fibroblast 
proliferation and epidermal 
differentiation of ADSC showed early 













In vitro studies 
Activity against S. aureus in skin 
model with low toxicity towards 
keratinocytes.  
[134] 
Polymer abbreviations: PCL= Polycaprolactone; PEG= Polyethylene glycol; PLGA= 
poly(lactic- co -glycolic acid); PVA= Polyvinyl alcohol; PVAc= Poly(vinyl acetate); PLLA= 
Poly(ʟ-lactic acid); PLLCL= poly(L-lactic acid)-co-poly-(ε-caprolactone); PEO=poly ethylene 




2.9 Mesenchymal stem cells and their properties 
MSCs are a heterogeneous population of adult "fibroblast-like" cells that can mature 
along multiple differential pathways according to their trophic activity. They were 
first identified in the bone marrow by Frienstein et. al. [15] and have since been found 
to be have trilineage differentiation potential by Pittenger et al in 1999 [135]. They 
are found at a density of 0.001 to 0.01% in the bone marrow nucleated cells or 1 per 
33,000 nucleated cells [136]. There are an estimated 300 colony forming MSCs per 
milliliter (mL) of bone marrow aspirate.  
 
 
Fig. 8: The estimated changes of BM-MSC populations at different age groups. Reprinted by 
permission from John Wiley and Sons: [Journal of Cellular Physiology, 
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-4652] [137], copyright (2007). 
 
MSCs have been found in a variety of other adult tissues such as adipose tissue [138], 
extra-fetal tissue (such as amniotic fluid[139], Wharton jelly [140], placenta [141]), 
dental gingival[142], hair follicles and dermis [143]. MSC populations are highly 
diverse and many groups have shown that there are significant donor-to-donor and 
intra-population heterogeneity [144]. Extraction location, methods and media 
components may also cause differences in MSC phenotypes and differentiation 
potential [145,146]. In order to have a more uniform classification of MSCs, the 
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Mesenchymal and Tissue Stem Cell Committee of the International Society for 
Cellular Therapy released a three component criteria that defines a MSC.  
A mesenchymal stem cell should fulfill the following three requirements:  
1) Plastic adherence 
2) Cellular markers 
 >95% positive for CD105, CD73, CD90 
 >98% negative for CD45, CD34, CD14, CD11b, CD79a, CD19, HLA-DR 
3) Differentiation into osteoblast, adipocyte, chondrocyte under standard in-vitro 
conditions.  
 
2.10 MSCs' role in wound healing 
2.10.1 MSCs can be mobilized into the peripheral blood during skin injury 
Mesenchymal precursor cells were first reported to be found in peripheral blood of 
patients that underwent chemotherapy and GM-CSF administration by Fernandez et 
al in 1997 [147]. Since then, there were multiple efforts to isolate the circulating, non-
hematopoietic precursor cell type, some successful, others not [148].  
 
In 2006, Mansilla et al. reported that blood stream cells that are phenotypically 
identical to bone marrow MSCs were found in increased percentages in the peripheral 
circulation of 15 patients who suffered from acute burn wounds. The amount of 
immobilized cells from these patients were reported to be proportionate to the size 
and degree of severity of the burn injury and younger patients were also reported to 
have greater percentage of peripheral MSCs [149]. Hamou et al. then studied the 
source of circulatory MSCs by looking for MSCs (defined by  lin-/Sca-1+/CD45- 
cells) after an ischemic injury is made on mice [150]. They showed that after an 
ischemic injury, there was a 4 fold decrease in bone marrow MSCs after 3 days that 
returned to baseline after 14 days. In the circulatory blood on the other hand, there 
was a 6 fold increase 7 days after injury that returns to normal after day 14. The 
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wound site on the other hand saw a 10 fold increase in MSCs 2 days post-injury that 
plateau after day 7 and returns to normal after day 20. Hematopoietic stem cells 
(defined as lin−/Sca-1+/c-Kit+/CD45+ cells) on the other hand showed minimal 
decrease in the bone marrow and minimal increase in the circulation and wound site 
indicating that MSCs from the bone marrow was mobilized after an injury. They 
further showed that in a green fluorescent protein (GFP)/wild type parabiotic muse 
model, GFP+ cells were found engrafting into the ischemic flap on the wild type 
mouse, suggesting that bone marrow derived MSC contribute at least partly to the 
population of MSCs in the wound site. The mechanism in which BM-MSCs are 
mobilized into the blood stream have largely been accredited to the SDF-1α-CXCR 
axis and HGF-c-met signaling axis [151]. Conditions that have been reported to 
facilitate MSC mobilization and homing includes inflammation [8] and hypoxia [9].   
 
2.10.2 MSCs selectively home to wound sites 
The mechanism for the localization and homing of MSCs into wound sites have not 
be fully understood. In fact, several groups have reported that most of the 
intravenously infused MSCs become passively entrapped in the lungs due to their 
large size and repertoire of cell-surface adhesion receptors before being relocated into 
other organs such as the liver and the spleen [152,153]. Amongst which, much of the 
cells were no longer viable after exiting the lungs, resulting in only a small 
percentage of infused MSC (< 1%) reaching the target tissue [154]. 
 
Despite low engraftment numbers, active arrestment of MSCs in inflamed tissues 
have been reported. Ruster et al. [155] showed that active arrestment of MSCs in 
blood vessels relies on P-selectin-dependent rolling and adhesion of MSCs on 
endothelial cells. This firm attachment of MSCs was increased when the endothelial 
cells were pre-treated with TNF-α, indicating that MSCs have a higher tendency to 
arrest in vasculature of inflamed tissues. In vivo studies by the same group also 
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showed significant reduction in the levels of MSC rolling in P-selectin-/- mice. Like 
Segers et al. [156], they showed that VLA-4 integrin and VCAM-1 integrin receptor 
play a dominant role in effecting adhesion of MSCs to vasculature walls. CD29, 
integrin-β1 have also been shown to be involved in MSC recruitment into tissues 
even though the exact pathway have not been clearly elucidated [157,158]. 
 
2.10.3 MSCs administration improves wound healing 
A large collection of studies have shown that mesenchymal stem cells improved 
wound healing and they have been summarized in Table 4. In general, it was found 
that MSC administration would improve wound healing throughout the whole process 
with groups reporting increased granulation tissue formation, accelerated wound 
repair and increased quality of wound repair (manifested by improved collagen 
deposition morphology and increased tensile strength in repaired wounds).  
 
It was also observed that while systemic MSC administration showed positive wound 
closure results, topical injection of MSCs could possibly further improve on the 
efficacy of the cells [10]. When MSCs were administered on a hydrogel scaffold, the 
efficacy was improved and the administered cells retained viable for a longer time 
[11]. The efficacy of MSC treatment appeared to be dose dependent where a critical 
dose of cells would be necessary to see improvements [159,160]. 
 
The mechanism in which MSCs contribute to wound healing have been largely 
attributed to its paracrine secretion of growth factors and cytokines that served to 
modulate the wound environment at its different stages during healing [161]. Some 
differentiation of MSCs into skin cells were also reported but to date, long term 




Table 4: Summary of studies for the treatment of in vivo skin wounds with mesenchymal stem 
cell therapy. [162] 
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application via 
fibrin spray 
Complete healing of 
acute wounds, 
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2.10.4 MSCs are immuneregulators 
MSCs were found to be potently immunosuppressive when stimulated by activated 
lymphocytes or IFN-γ when combined with TNF-α, IL-1α or IL-1β  [196]. Stimulated 
MSCs express high levels of several chemokines like the multifunctional anti-
inflammatory protein TNF-α stimulated gene/protein 6 (TSG-6) [197] and inducible 
nitric oxide synthase (iNOS) that drives T cell migration towards MSCs  and in turn 
suppress the responsiveness of T cells due to the presence of high levels of nitric 
oxide. Cytokines from MSCs also suppressed T cell's further production of 
inflammatory cytokines such as IFN-γ, IL-4 and TNF-α.  
 
Interestingly, macrophages co-cultured with MSCs showed phenotypes of 
alternatively activated M2 macrophages and secreted high levels of IL-10 and low 
levels of IL-12 and have a high phagocytotic activity [198]. Zhang et al. showed in a 
splinted mouse full thickness skin wound model that skin tissue samples and tissue 
lysates indicated an M2 macrophage phenotype in the wound environment when the 
cells were treated with gingival-derived MSCs [169]. This conversion was probably 
due to prostaglandin E2 (PGE2) secreted by activated macrophages [197]. In fact, 
family derived ex vivo MSCs have been shown in clinical practice to reduce the 
symptoms of graft-versus-host disease (GvHD, a lethal complication of 
immunorejection of allogenic organ implants [199]. The efficacy of MSC treatment 
in GvHD seems to be dose-dependent [200]. 
 
MSCs also lack the expression of human leukocyte antigen-DR (HLA-DR), a ligand 
for the T cell receptor in eliciting immunoresponses to foreign cells. Antibodies 
against the antibody of HLA-DR that blocks its presentation on cell surfaces have 
been shown to prolong the survival of organ implants [201]. The absence of HLA-DR 
hence allow MSCs to not be recognized by T-cells of its allogenic recipient. MSCs 
also fail to elicit a T-cell response in vitro [202] and also help to suppress T-cell 
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proliferation in mixed cell cultures [203] and are hence termed to be 
immunoprivileged.  
 
2.10.5 MSCs improve on granulation tissue quality and formation 
Real time-polymerase chain reaction (RT-PCR) analysis by Liu et al.[204] 
demonstrated that LPS, IL1-α and TGF-α stimulate the secretion of TGF-β1, EGF, 
VEGF, PDGF, KGF, FGF and HGF by MSCs. Addition of wound superfusate to 
MSCs cultured in vitro also caused TGF-β1, EGF and VEGF secretion by MSCs that 
is not secreted by MSCs in normal conditions. These cytokines in turn function as 
chemoattractants to encourage the migration of fibroblasts, macrophages and 
endothelial cells. Smith et al showed that in chemotaxis assays, fibroblasts migrate 
towards MSCs and upregulate the expression of integrin α7 while downregulating 
Intercellular Adhesion Molecule 1 (ICAM1), Vascular cell adhesion protein 
(VCAM1) and MMP11 [205]. MSC conditioned media have also been shown by 
Walter et al.[206] to accelerate the migration of keratinocytes and fibroblasts in in-
vitro scratch assays indicating that MSC's mode of action is via paracrine secretion. 
This notion was further reinforced when Tredget and group showed in a mice wound 
healing model that BM-MSC-conditioned media accelerated wound healing 
compared to pre-conditioned media or fibroblast-conditioned media[165].  
 
MSCs also have a direct paracrine influence on the extracellular matrix composition 
inside the wound. Conditioned media from adipose-derived stem cells (ADSCs) and 
MSCs alike encouraged the gene expression of type I and type III collagens, elastins 
as well as fibronectin by fibroblasts [207,208]. MSCs also seem to impose a survival 
benefit to fibroblasts in face of oxidative stresses [208]. Unfortunately, 
overexpression of collagen may lead to fibrosis and Ding et al. found that co-
culturing MSCs with deep dermal fibroblasts enhanced the fibrotic behavior of the 
fibroblasts, leading them to suggest that MSCs can have a possible involvement in the 
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pathological development of hypertrophic scars [209]. Interestingly, most reports on 
the application of MSCs in skin injuries reported decrease scarring [210]. HGF and 
PGE2 secretion by MSCs are also linked to decrease fibrosis through downregulation 
of collagen production in fibroblasts [211-213].   
 
2.10.6 MSCs improve neovascularization and angiogenesis 
MSCs were shown to improve blood supply to the wound's granulation tissue 
[187,191]. Sasaki et al. found co-location of systemically injected GFP+ MSCs with 
CD31 endothelial cell markers [167] suggesting that MSCs may transdifferentiate 
into endothelial cells. In vitro, endothelial growth media primed MSCs when seeded 
on matrigel were able to form tube-like structures like bone fide endothelial cells 
[214].   
 
Wu et al. on the other hand found high levels of proangiogenic factors such as VEGF 
and angiopoietin-1 in MSCs through both ribonucleic acid (RNA) and protein 
analysis [164]. Co-culturing MSCs with endothelial cells supports the development 
and stabilization of vascular tube-like structures in culture [215] and conditioned 
media from MSCs improved endothelial migration, extracellular matrix invasion, 
proliferation and survival in vitro [216]. These data suggests that MSCs secrete 
paracrine factors to enhance neovascularization and angiogenesis of the wound bed. 
 
 2.10.7 MSC may transiently differentiate into skin cells 
Quite a number of groups have shown in animal experiments that MSCs engraft in 
the wound site and express markers that correspond to epithelial cells. Wu et al. [164] 
injected GFP-expressing MSCs intradermally at the periphery of skin wounds in 
normal and diabetic mice.  Apart from enhanced cutaneous regeneration, the authors 
observed that the GFP-expressing cells co-localized with epithelial protein 
cytokeratin and even commented that the GFP-positive MSCs appear to form 
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"structures that resembled developing sweat or sebaceous glands" that mature over a 
14 day period. When the wound site was excised, dispersed to single cell suspensions 
and analysed by fluorescence-assisted cell sorting (FACS), while 27% of the injected 
1 million BM-MSCs were observed to be engrafted at the wound site at 7 days, the 
percentage of cells fell to 7.6% at 14 days and at 28 days, only 2.5% of the implanted 
cells remained at the wound site.  
 
In another work by Fu et al.[190], 5-bromodeoxyuridine (5-BrdU) labeled MSCs 
were autografted into full-thickness skin wounds of minipigs. The authors observed 
increase in re-epithelialization speed, increased number of epidermal ridges in the 
repaired skin with 5-BrdU positive cells co-localizing with cells that express Factor 
VIII (an endothelial cell marker) and cytokeratin. However, quantitative analysis by 
photographing 5 random fields and counting for dual-labeled cells showed that not 
only is the percentage of "transdifferentiated" cells small (maximum 1.49% of BrdU 
positive cells were positive for cytokeratin at day 14, the number of dual-labeled cells 





Investigating mesenchymal stem 
cells' extracellular matrix role in 
modulating wound healing 
 
3.1 Introduction 
MSCs help wound healing. The mechanisms in which MSCs does so was discussed 
in detail in Chapter 2. Amongst them, paracrine factors such as cytokines and growth 
factors that MSCs secrete was attributed as the main mechanism by many. Ries et al 
investigated how the presence of inflammatory cytokines like TGF-β1, TNF-α, IL-1β 
and SDF-1α influenced the secretion of matrix metalloproteases and their inhibitors 
[8]. They showed that inflammatory cytokines are chemoattractants of MSCs that 
helped to increase their invasive properties into a wound site. Their data indicated 
that MSCs, like fibroblasts, respond to wound cytokines by changing their secretion 
profile.  
 
Like fibroblasts, MSCs are mesenchymal cells that secrete a large amount of ECM. 
Chen et al in a series of studies showed that MSCs deposit ECMs in vitro that 
enhances MSC self-renewal while standard Col I coating does not [217]. Their data 
suggests that MSCs secrete ECM that contains various information that are able to 
direct cell metabolism and lineage. The role of MSCs in terms of ECM modulation 
and secretion in a wound environment however have not been studied in detail.  
There is no information as to whether ECM proteins secreted by MSCs change with 
exposure to different cytokines. 
 
ECM plays an important role in facilitating wound healing. Disrupted ECM in a 
wound kicks start the coagulation process including platelet degranulation and signals 
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keratinocyte migration to close the wound. ECM also regulates the progression of 
wound healing by providing attachment substrates necessary for cell mobility into the 
wound. High amounts of proteases that degrades ECM in the wound bed are a major 
reason why chronic diabetic wounds do not close. Excessive deposition of ECM 
during the wound healing process, on the other hand, results in hypertrophic scarring.   
 
I am interested to know if MSCs would be able to secrete ECM that are more 
conducive for re-epithelialization when placed into a wound environment. The effect 
on NHEK proliferation and motility of the various ECMs secreted by MSCs pre-
activated with wound healing cytokines (TGF-β1 and TNF-α) was studied. TGF-β1 
and TNF-α were chosen as representatives of wound cytokines due to the major role 
they play in different stages of wound healing. Their effect on ECM secreted by HDF 
are also well understood. In order to isolate the effect of secreted ECM on NHEKs 
from that of cell-cell interaction, cell layers were decellularized to leave behind only 
the ECM but no living cell components. The role of MSCs in cell-cell interaction 
with NHEK was then studied using a direct co-culture of NHEKs and MSCs. 
 
MSCs are hypothesized to deposit ECM that are conducive to wound healing under 
the influence of wound cytokine and its interaction with NHEKs. This work showed 
that MSCs are strong ECM secretors and the deposited ECM has a different profile 
from the ECM deposited by HDF. Even though ECMs deposited by MSCs and HDFs 
support NHEK proliferation, the ECM deposited by MSCs is a potent stimulant for 
NHEK migration, an important consideration in wound healing. I also showed that 
when MSCs are in close contact with NHEKs, skin specific dermal-epidermal 
junction (DEJ)-related ECM deposits are produced. These data suggest that the ECM 
secreted by MSCs can play a special role in wound healing.    
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3.2 Materials and Methods 
3.2.1 Cell Culture 
Human bone marrow-derived mesenchymal stem cells (MSCs) were obtained from 
the Therapeutic Tissue Engineering Laboratory under the Department of Orthopaedic 
Surgery, National University Hospital of Singapore (NUH) (section 3.3.1 to section 
3.3.5) or purchased from Lonza (PT-2501, Basel, Switzerland) (section 3.3.6). The 
MSCs were expanded in low glucose (LG) Dulbecco's Modified Eagle Medium 
(DMEM) media supplemented with 10% fetal bovine serum (FBS), 100 IU/ml 
penicillin and 100 μg/ml streptomycin (GIBCO, Invitrogen Corporation, USA) until 
ready for use. The cells from NUH were used at passage 4-5 while the Lonza cells 
were used at passage 6-7 for this study. Human fetal foreskin dermal fibroblasts 
(HDF) were purchased from ATCC (Manassas, VA, USA) and expanded in high 
glucose (HG) DMEM media supplemented with 10% FBS, 100 IU/ml penicillin and 
100 μg/ml streptomycin (GIBCO, Invitrogen Corporation, USA) until ready for use. 
Cells at passage 8-9 were used for the studies. Normal Human Epidermal 
Keratinocytes (NHEK) adult, (pooled) were purchased from Promocell (Heidelberg, 
Germany) and expanded in Keratinocyte Growth Medium 2 Kit (KGM, Promocell) 
until ready for use. Cells are passage +4 to +5 were used for the studies. Cells were 
incubated under standard culture conditions of 37°C in a sterile humidified incubator 
with 5% CO2. 
 




3.2.2 Extracellular Matrix (ECM) synthesis 
HDFs or MSCs suspended in blank HG DMEM were plated at 40 000 cells per well 
in 24-well plates (Greiner bio-one, FL, USA). After an attachment period of one day 
cells were washed once with HBSS and changed to induction media that consisted of 
HG DMEM with 1% penicillin/streptomycin and either 5 ng/mL TGF-β1 or 10 
ng/mL TNF-α (RnD Systems, Minneapolis, MN, USA). After 24 hours of induction, 
cells were washed with HBSS twice before adding HG DMEM supplemented with 
1% penicillin/streptomycin, 30 µg/ml L-Ascorbic Acid Phosphate Magnesium Salt 
(Vit C, WAKO, Japan), 25 mg/ml Ficoll 400 (GE Healthcare, USA) and 37.5 mg/ml 
Ficoll 70 (GE Healthcare,USA). The supplementation of Ficoll will hence be termed 
as macromolecular crowding (MMC) from here on. Previous work [218] from our 
laboratory has shown that fibroblasts secrete exuberant amount of ECM under MMC. 
The cells were then allowed to secrete and deposit ECM for 3 days further. Thus, the 
bulk of the ECM used in subsequent studies were deposited during the 3 days of 
MMC treatment.   
 
3.2.3 Decellularizing leaving behind ECM 
HDFs and MSCs cultured for 3 days under MMC were decellularized of the cells 
using a decellularizing protocol with ammonium hydroxide and Triton X-100. First, 
cell layers were washed thrice with HBSS. Subsequently the cell layers were lysed 
with 0.02 M ammonia hydroxide (NH4OH) (Sigma-Aldrich, MO, USA) in a 0.5% 
Triton X-100 (Biorad, CA, USA) solution for 5 minutes at 37°C. The lysis solution 
was supplemented with 0.5x protease inhibitors (PI) (Complete, Roche, Basel, 
Switzerland) according to a protocol modified from that by Chen et al [217]. The 
lysed ECM were carefully washed twice by severe dilution with hank's balanced salt 
solution (HBSS). After 30 minutes of incubation at 37°C with 0.02 mg/ml DNAse 
(USBiological, MA, USA) with 0.16x PI and 4 µM MgCl2 (Sigma-Aldrich) cells 
were carefully washed twice by severe dilution with phosphate buffered saline (PBS) 
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and either fixed with 10 minutes ice cold methanol fixation or used for further 
experiments. 
 
3.2.4 Immunocytochemistry (ICC) staining for ECM components 
Immunofluorescence staining of Col I, Col III, Col IV, Col VII, Laminin 3,3,2 and 
FN was performed on cells or ECM layers fixed with ice cold methanol. Monoclonal 
mouse anti-collagen I [clone COL-1] (1:1000 dilution), monoclonal mouse anti-
collagen III [clone FH-7A] (1:1000 dilution) (Sigma-Aldrich), polyclonal rabbit anti-
collagen IV (1:500 dilution), monoclonal mouse anti-collagen VII (1:100 dilution) 
[clone LH7.2], monoclonal mouse anti-epiligrin [clone P3H9-2] (anti-laminin 3,3,2, 
1:200 dilution) (Abcam, Cambridge, England), polyclonal rabbit anti-collagen I (1:50 
dilution) (Milipore, Darmstadt, Germany) and polyclonal rabbit anti-fibronectin 
(1:1000 dilution) (Dako, Denmark) were used as primary antibodies. Alexafluor 564 
goat-anti-mouse and Alexafluor 488 chicken-anti-rabbit (Life Technologies, CA, 
USA) were used as secondary antibodies in a 1:400 dilution. 4',6-diamidino-2-
phenylindole (DAPI) (0.5 µg/mL) was used as a counterstain for cell nuclei. 
Fluorescent staining area and intensity was determined with the PHERAstar 
microplate reader with a focusing lens system (BMG LABTECH, Germany) as 
previously described by Wang et. al. [219]. Fluorescent images were made with an 
Olympus IX71 microscope and a Olympus DP70 digital camera. Samples stained 
without primary antibodies were used as a staining control.  
 
3.2.5 NHEK proliferation assay 
ECM produced by MSC and HDF pre-activated by 5 ng/mL TGF-β1 or 10 ng/mL 
TNF-α or not pre-activated were decellularized under sterile conditions as described 
under section 2.3.. NHEKs were then seeded at 10.000 cells/24 well for the 
proliferation assay in 0.5 mL Keratinocyte Growth Media (KGM) without epidermal 
growth factor and insulin supplementation (hereby termed as KGM(-) media). On day 
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1, 3, 5, and 7 post-seeding, the cells were washed and a live cell metabolism assay 
was performed using alamar blue (Invitrogen, Life Technologies, CA, USA) 
according to the manufacturer's protocol and read using a Infinite® 200 PRO 
microplate reader and the iControlTM software. After the assay, the cells were washed 
once with HBSS and fresh KGM(-) media was replenished. After a further 7 days in 
culture, the cells were lysed with a proteinase K, Triton X-100 buffer and its DNA 
content was quantified with picogreen assay (Invitrogen).   
 
3.2.6 NHEK motility assay 
In order to determine the motility of the NHEK cells seeded on the decellularized 
matrices, a time-lapsed microscopy technique using the NIKON imaging center at 
Singapore BioImaging Consortium. 3000 cells/well of NHEK were seeded on 
decellularized matrices and allowed to adhere overnight in a 5% CO2 temperature 
controlled incubator at 37°C. The cells were stained using CellTrackerTM Red 
CMTPX (Invitrogen, gift from Dr. Filip Laco) at a dilution of 1:20 000 in KBM 
medium (Promocell, Germany) for 30 minutes prior to imaging. Phase contrast and 
fluorescent images were captured with a Nikon Eclipse TI-E inverted microscope 
including a photometrics cool snap HQ fast high-resolution fluorescence microscopy 
camera. During the period of image acquisition, the cells were incubated with a Tokai 
incubation system that maintained a 5% CO2 atmosphere at 37°C. Images were made 
every 15 minutes for 24 hours and analyzed with NIS element and SQ bioanalysis 
software that recorded the total distance moved per cell. Only cells that were tracked 
by the software for 90 time points and above (out of 97 time points) were included for 
the study.  
  
3.2.7 Mesenchymal cell (MSCs and HDFs) in direct co-culture with NHEK 
Direct co-culture was performed in order to investigate the ECM secretion profile 
when MSCs was co-cultured with NHEKs. HDFs was used instead of MSCs as a 
51 
 
control. 10,000 MSCs or HDFs were seeded in each well of a 24 well plate in HG 
DMEM supplemented with 10% FBS and 100 IU/ml penicillin and 100 μg/ml 
streptomycin. After overnight adherence, 30 µg/ml L-Ascorbic Acid Phosphate 
Magnesium Salt, 25 mg/ml Ficoll 400 and 37.5 mg/ml Ficoll 70 was supplemented 
and the cells were allowed to deposit ECM for 3 days. On the 3rd day, 40,000 
NHEKs suspended in complete KGM were seeded into each well and given the time 
to adhere overnight. The next day, the culture media was changed to Green's media 
supplemented with 30 µg/ml L-Ascorbic Acid Phosphate Magnesium Salt, 25 mg/ml 
Ficoll 400 and 37.5 mg/ml Ficoll 70. Green's media contains 3 parts HG DMEM and 
1 part Ham's F12 media (Invitrogen) supplemented with 10% FBS, 1X GlutaMax, 
100 IU/ml penicillin and 100 μg/ml streptomycin, 180 µM adenine, 5 µg/mL insulin, 
5 µg/mL apo-transferrin, 1 µM 3,3’,5-triiodo-L-thyronine, 400 ng/mL hydrocortisone 
and 5 ng/mL EGF. A media change was performed on day 3 post addition of ficoll 
and the cells were fixed using ice cold methanol fixation on day 5. ICC was 






3.3.1 Macromolecular crowding (MMC) improved ECM deposition in the presence of 
ascorbic acid 
Deposition of ECM in conventional culture is rarely observed. In our laboratory, a 
system termed MMC was devised to increase in vitro deposition of  ECM [218]. In 
this chapter, this enabling technology was used for the series of ECM related studies. 
Fig. 10 shows the effect of Vit C and MMC on Col IV deposition by MSCs. The 
presence of Vit C stimulated the extracellular secretion of Col IV while ficoll MMC 
enhanced the deposition of Col IV in culture.   
 
 
Fig. 10: Immunostaining of Col IV deposition with or without the supplementation of  Vit C 
and MMC. Vit C supplementation enhanced the extracellular secretion of collagen while 
addition of MMC enhanced the deposition of collagen on the cell layer. Data are 






3.3.2 ECM characterization  
The influence of wound cytokines like TNF-α and TGF-β1 on ECM production by 
MSCs was investigated by pre-activating the cells with cytokines for 24 hours and 
allowing the them to deposit ECM for 3 days under Vit C and MMC 
supplementation. The deposition profiles of Col I, Col III, Col IV and fibronectin 
(FN) were evaluated by immunocytochemistry (ICC) and quantified via spectroscopic 
means using the Pherastar microplate reader [219]. These ECM proteins were 
selected for analysis as they are the main structural ECM components of the skin. 
 
TGF-β1 increases Col I while TNF-α decreases MSC Col I but increases HDFs Col I 
The effect of wound cytokines on Col I deposition is shown in Fig. 11. MSCs were 
significantly stronger secretors of Col I than HDFs. Both MSCs and HDFs showed 
the highest amount of Col I deposition after TGF-β1 pre-activation with HDF 
increasing its deposition by more than 5 times and MSCs doubling its Col I 
deposition. The two cell types however had differential responses to TNF-α 
stimulation. Under the influence of TNF-α, HDFs showed a 50% increase of Col I 
deposition. Col I deposition by MSCs on the other hand had a slight decrease in 
quantity when pre-activated with TNF-α.    
 
TGF-β1 increases MSC Col III dramatically while TNF-α increased MSC and HDF 
Col III slightly 
Col III is the first collagen type deposited in a wound post-injury. In culture, its 
deposition is usually very low. Indeed, in this study, Col III deposition in non-
activated HDFs and MSCs alike were very low (Fig. 12). However, Col III secretion 
was increased by more than 20 folds in TGF-β1 pre-activated MSCs. No significant 
increases were identified in HDFs pre-activated by TGF-β1. Slight increases in Col 




Fig. 11: A) The effect of TGF-β1 or TNF-α pre-activation on the deposition of Col I in HDFs 
and MSCs. The graph is a quantification of the immunostaining presented in fold changes 
with respect to the deposition in non-activated HDFs. The pictures at the bottom are 
representative images of the staining profile. B) Statistical analaysis of Col I production when 
cells were pre-activated with TGF-β1 or TNF-α. A + sign indicates an increase of the first 
condition compared to the second while a - sign indicates a decrease. Data represent the mean 
(n = 3), and error bars represent standard deviation. (Student's t-test *: p<0.05; **: p<0.01; 







Fig. 12: A) The effect of TGF-β1 or TNF-α stimulation on the pre-activation of Col III in 
HDFs and MSCs. The graph is a quantification of the immunostaining presented in fold 
changes with respect to the deposition in non-activated HDFs. The pictures at the bottom are 
representative images of the staining profile. B) Statistical analaysis of Col III production 
when cells were pre-activated with TGF-β1 or TNF-α. A + sign indicates an increase of the 
first condition compared to the second while an = sign indicates that the two conditions 
compared were not significantly different. Data represent the mean (n = 3), and error bars 
represent standard deviation. (Student's t-test *: p<0.05; **: p<0.01; NS=not significant, 







TGF-β1 increased Col IV deposition while TNF-α caused decreases in Col IV 
deposition by MSCs 
Intensity analysis of Col IV staining (Fig. 13) showed an increase in Col IV under 
influence of TGF-β1 for both cell types even though the increase was significant only 
for MSCs. No difference in Col IV deposition by HDFs was seen under the influence 
of TNF-α while MSCs showed a slight decrease in secretion when pre-activated by 
TNF-α. MSCs generally deposited more Col IV than HDFs.  
 
TGF-β1 and TNF-α have minimal influence on FN deposition 
Fibronectin (FN) is amongst the first ECM proteins deposited by mesenchymal cells 
when they are seeded in vitro (laboratory observations). In our study, FN deposition 
by HDFs showed a slight increase after TGF-β1 pre-activation (Fig. 14) while no 
significant changes were observed after TNF-α stimulation. Fibronectin deposition 
changes in response to cytokine stimulation on the other hand by MSCs was not 
observed. The influence of wound cytokines TGF-β1 and TNF-α on FN deposition 






Fig. 13: A) The effect of TGF-β1 or TNF-α pre-activation on the deposition of Col IV in 
HDFs and MSCs. The graph is a quantification of the immunostaining presented in fold 
changes with respect to the deposition in non-activated HDFs. The pictures at the bottom are 
representative images of the staining profile. B) Statistical analaysis of Col IV production 
when cells were pre-activated with TGF-β1 or TNF-α. A + sign indicates an increase of the 
first condition compared to the second while a - sign indicates a decrease. Data represent the 
mean (n = 3), and error bars represent standard deviation. (Student's t-test *: p<0.05; **: 






Fig. 14: A) The effect of TGF-β1 or TNF-α pre-activation on the deposition of FN in HDFs 
and MSCs. The graph is a quantification of the immunostaining presented in fold changes 
with respect to the deposition in non-activated HDFs. The pictures at the bottom are 
representative images of the staining profile. B) Statistical analaysis of FN production when 
cells were pre-activated with TGF-β1 or TNF-α. A + sign indicates an increase of the first 
condition compared to the second; a - sign indicates a decrease while an = sign indicates that 
the two conditions compared were not significantly different. Data represent the mean (n = 3), 
and error bars represent standard deviation. (Student's t-test *: p<0.05; **: p<0.01; NS=not 






Fig. 15: Comparison between the ECM deposition of HDFs (top) and MSCs (bottom) when 
pre-activated by either TGF-β1 (orange) or TNF-α (green). The graphs are a collation of the 
data presented in Fig. 11-14. The quantification of immunostaining of each deposited ECM is 
presented in fold changes with respect to that of control (non-activated) cells. The data 
showed 2 differences between the deposition profile of MSCs compared to HDFs: 1) MSCs 
decreased deposition of Col I when pre-activated by TNF-α, 2) MSCs dramatically increased 






3.3.3 Decellularization had minimal effect on MSC ECM but caused some loss in 
HDF ECM  
In order to assess the influence of the deceullularization protocol on deposited ECM, 
ICC was performed on the same batch of cells before and after deceullularization and 
quantified for staining area and intensity using spectrometry (Fig. 16-20). While the 
trend of ECM deposition in Fig. 16-20 is similar to that shown in Fig. 11-14, the 
differences in fold changes between the conditions and samples are reflective of 
biological and experimental variations.  
 
On the whole, MSC derived ECM appeared to withstand the deceullularization 
protocol more than that of the HDF deposited ECM. Col I staining did not show clear 
differences before and after deceullularization, indicating that the decellularization 
protocol did not alter the Col I component of the ECM (Fig. 16, 17, 19). The amount 
of Col III was extremely low in this set of data (in contrast to that in Fig. 12), this is 
indicative of the wide biological variations faced typically when dealing with primary 
cell types. Nevertheless, the staining before and after lysis did not change visibly 
significantly (Fig. 18, 20). Col IV on the other hand seemed to be more susceptible to 
the deceullularization protocol. While the MSC Col IV component was resistant to 
deceullularization, HDF's Col IV was decreased (Fig. 16, 17 and 19). FN was the 
most influenced by the deceullularization protocol with slight decrease and tears in 
the FN composition in both MSC and HDF decellularized ECM (Fig. 16, 18, 20).  
 
Quantification of the ECM staining was reflective of what was observed under the 
microscope for Col I, Col IV and FN (Fig. 16). Quantification however was not 
possible for Col III in this series of experiment due to very weak staining for Col III 
that led to high background noises making quantification using the PheraStar not 




Fig. 16: Quantification of ECM staining in HDFs and MSCs before and after 
deceullularization. Some loss of ECM was found in HDF deposited ECM after 
deceullularization while MSC deposited ECMs held up quite well. The decellularized matrices 
were generally reflective of the original pre-decellularized matrices secreted and deposited by 






Fig. 17: Immunostaining of Col I and Col IV present on non-decellularized and decellularized 
HDF deposited ECM. The deceullularization protocol had minimal effect on Col I while some 
Col IV was lost. The lack of DAPI staining in the decellularized ECMs indicated success of 






Fig. 18: Immunostaining of Col III and FN present on non-decellularized and decellularized 
HDF deposited ECM. The deceullularization protocol had minimal effect on Col III while 
some FN was lost. The lack of DAPI staining in the decellularized ECMs indicated success of 








Fig. 19: Immunostaining of Col I and Col IV present on non-decellularized and decellularized 
MSC deposited ECM. The deceullularization protocol had minimal effect on both Col I and 
Col IV. The lack of DAPI staining in the decellularized ECMs indicated success of the 





Fig. 20: Immunostaining of Col III and FN present on non-decellularized and decellularized 
MSC deposited ECM. The deceullularization protocol appeared to have minimal effect on Col 
III despite extremely low deposition while some FN was lost. The lack of DAPI staining in the 
decellularized ECMs indicated success of the deceullularization protocol. Data are 








3.3.4 Effect of decellularized ECMs on NHEK metabolism and proliferation  
The progressive total metabolism of NHEK seeded in each well of decellularized 
matrix was investigated using the alamar blue assay. Alamar blue is a cell viability 
indicator that uses the reducing power of metabolically active living cells to convert 
resazurin to the fluorescent molecule, resorufin. The resorufin can then be quantified 
by absorbance using a microplate reader. Greater conversion of resazurin indicates 
stronger reducing power of the cell population and greater metabolism. An advantage 
of using the alamar blue assay, is that it does not significantly affect cell viability and 
the same cells can be repeatedly assayed for the study period allowing for consistency 
throughout the study.  
 
In Fig. 21, slight but significant increase in cell metabolism was observed in NHEKs 
seeded on plastic but not when the cells were seeded on decellularized ECM 
deposited by TGF-β1 pre-activated cells. The metabolism of NHEKs seeded on 
decellularized ECM secreted by MSCs pre-activated by TGF-β1 had a significant 
decrease in metabolism over time from 14% substrate reduction on day 1 to only 8% 
substrate reduction on day 7. NHEKs seeded on decellularized ECM secreted by non-
activated cells and TNF-α pre-activated cells on the other hand showed a steady 






Fig. 21: Alamar blue assay of NHEKs grown on decellularized ECM deposited by HDFs (red) 
or MSCs (blue) over a period of 7 days (marked at the base of each bar). NHEKs grown on 
decellularized ECMs secreted by Ctrl (non-activated) and TNF-α pre-activated HDFs and 
MSCs showed increase cell viability over a 7 day period. No increase in cell viability however 
was observed in TGF-β pre-activated HDF or MSC deposited ECMs. Data represent the mean 
(n = 3), and error bars represent standard deviation. (*: student t-test p<0.05) 
 
The number of cells 7 days post-seeding was quantified using picogreen assay that 
measures the concentration of double stranded DNA in each sample (Fig. 22). The 
amount of DNA tallied with what was observed using the alamar blue assay. As 
compared to when grown on plastic substrates, NHEKs proliferated better when 
seeded on decellularized ECM deposited by TNF-α pre-activated (2 folds increase) or 
non-activated control cells (3 folds increase). However, decellularized ECM 
deposited by TGF-β1 pre-activated HDFs and MSCs alike attenuated the growth of 
NHEKs. There were significantly lower number of NHEKs growing on ECM 
deposited by TGF-β1 pre-activated cells than on plastic substrate on day 7. While 
TNF-α significantly decreased the proliferation stimulatory effect of HDF deposited 
ECM, there was no significant difference between the proliferation of NHEKs grown 
on decellularized ECM from TNF-α pre-activated MSCs compared to that from cells 
that were non-activated. Decellularized ECM from both MSCs and HDFs pre-
activated by TGF-β1 however significantly decreased the number of NHEKs after 7 
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days of culture compared to that from non-activated cells. The proliferation inhibitory 
effect of ECM deposited by MSCs pre-activated with TGF-β1 was significantly 
stronger than that of similarly pre-activated HDFs.   
 
 
Fig. 22: (top)Picogreen assay quantifying the amount of DNA present in samples of NHEKs 
grown on decellularized ECM secreted by HDFs (red) or MSCs (blue) 7 days after seeding. 
(bottom) Statistical analaysis of NHEK DNA amounts (reflective of cell numbers) when 
grown on decellularized ECM pre-activated with TGF-β1 or TNF-α (bottom).  A + sign 
indicates an increase of the first condition compared to the second; a - sign indicates a 
decrease while an = sign indicates that the two conditions compared were not significantly 
different. Data represent the mean (n = 3), and error bars represent standard deviation.  




3.3.5 Effect of  decellularized ECMs on the motility of NHEK 
Due to the fragile nature of decellularized matrices, it was not possible for technical 
reasons to get a directional migration of NHEKs from a standard substrate to the 
decellularized ECMs. Instead, a live cell tracking system was used to track the 
motility of cells. The read-out was given in terms of average total distance moved per 
cell of NHEKs seeded on the various decellularized ECMs. Decellularized ECMs 
across the board resulted in higher motility of NHEKs seeded on them as compared to 
those seeded on plastic substrates. In particular, TGF-β1 pre-activated HDFs and 
MSCs secreted ECMs that caused up to 3 folds higher motility in NHEKs than 
NHEKs seeded on tissue culture plastic. ECM deposited by non-activated and TNF-α 
pre-activated MSCs supported significantly higher NHEK motility than those seeded 
on ECMs secreted by HDFs under similar conditions. Decellularized ECMs secreted 
by MSCs whether pre-activated or not were not significantly different in their ability 
to increase NHEK motility (Fig. 23). When the individual cells were investigated 
(Fig. 24), it was observed that the increase in average total distance moved was due to 
an overall population wide increase in motility of the cells measured. This was 
substantiated by the overall right shift of the histograms recording the percentage of 
cells in the tracked population that moved total distances of fixed ranges. The data 
suggests that MSCs secrete an ECM that enhances NHEK motility greatly regardless 






Fig. 23: (top) Average distance moved per cell of NHEKs seeded on decellularized matrices 
secreted by HDFs (red) or MSCs (blue) recorded over a 24 hour period. (bottom) Statistical 
analysis of average distance moved by NHEKs when seeded on decellularized ECM deposited 
by MSC/HDF pre-activated with TGF-β1 or TNF-α.  A + sign indicates an increase of the first 
condition compared to the second. Data are representative of calculation involving 110-180 








[conventions: HDF TGF-β1 = decellularized ECM deposited by HDFs pre-activated with 
TGF-β1; HDF Ctrl = decellularized ECM deposited by non-acgtivated HDFs; HDF TNF-α = 
decellularized ECM deposited by HDFs pre-activated with TNF-α; similar conventions were 
used in decellularized MSC deposited ECM]. 
Fig. 24: Histogram showing the percentage of cells in the population measured that moved 
certain fixed ranges of distances over the 24 hour assay period. NHEKs seeded on HDF TGF-
β1 travelled more than those seeded on HDF TNF-α or HDF Ctrl. The histograms shifted to 
the right, suggesting that the increase in average motility was not due to a few extremely high 
motility cells but due to increased motility in the entire population. NHEKs seeded on MSC 
TNF-α and MSC Ctrl had significantly higher motility than cells seeded on the corresponding 
HDF deposited ECM that were similarly pre-activated. Data are representative of calculation 



































Total distance moved by the single NHEK of interest / µm 
72 
 
3.3.6 Direct co-culture assay of MSCs with NHEKs 
In order to understand the cell-cell interaction between MSCs and NHEKs, the two 
cell types were grown together in a direct co-culture assay. HDFs cultured in direct 
co-culture with NHEKs were used as a control. Ficoll MMC was used to encourage 
deposition of ECM proteins. Skin dermal-epidermal junction (DEJ) basement 
membrane proteins are expected to be deposited as a direct consequence of dermal-
epidermal-like interactions and hence DEJ related ECM components Col I, IV, VII 
and lam 3,3,2 [32]  were stained for using ICC in our direct co-culture studies.  
 
Fig. 25 shows the deposition of DEJ-related ECM components when HDFs, MSCs 
and NHEKs were cultured on their own in a monoculture. Through the microscopic 
images, it was observed that HDFs and MSCs deposited a large quantity of fibrillar 
Col I while NHEKs did not have significant deposition. While it appears as though 
NHEKs have some staining, it did not have the typical fibrillar structure of deposited 
Col I. Col VII on the other hand had some deposition in all three cell types that 
appears as stipples of protein (Fig. 25, 40X Col VII staining). HDFs and MSCs were 
major secretors of Col IV that adopted a web like morphology. The Col IV staining 
on NHEK cell layer on the other hand appeared to look like stains of collagen with no 
distinct structure. Lam 3,3,2 is exclusively secreted by NHEKs and appeared in areas 
that had no cells as shown by the lack of DAPI staining in majority of the microscope 





Fig. 25: Immunostaining of monoculture populations of HDFs, MSCs or NHEKs for ECM 
components, Col I and Col VII. Counterstaining was performed with DAPI to show cell 
location. The bottom row shows high magnification images at high exposure of Col VII 
staining. Col I was deposited by the mesenchymal cells, HDFs and MSCs. The staining in 
NHEKs appears to be very bright autoflourescence. Col VII staining was shown at an enlarged 
magnification of 40X as the staining was weak and appeared as very small stipples (white 
arrows) that can be found in the matrices of all three cell types at very low amounts. Data are 




Fig. 26: Immunostaining of monoculture populations of HDFs, MSCs or NHEKs for ECM 
components, Col IV and Lam 3,3,2. Counterstaining was performed with DAPI to show cell 
location. Col IV was deposited by HDFs and MSCs and had a fibrillar structure. There 
appeared to be some staining Col IV staining in NHEKs but without the fibrillar structure. 
Lam 3,3,2 on the other hand was deposited exclusively by NHEKs and was found in areas 
without DAPI staining. Data are representative of at least 3 replicates. 
 
Fig. 27 shows location profile of NHEKs (stained red with a pancytokeratin antibody) 
when in direct co-culture with MSCs and HDFs. The cells grew in a typical cluster 
structure similar to those observed when normal keratinocytes are seeded onto 
fibroblast feeder layers [220]. The cell clusters were close knitted and no "stray cells" 




Fig. 27: Immunostaining of NHEKs cocultured with HDFs or MSCs. Pancytokeratin stains 
specifically for NHEKs while DAPI stains all cell nuclei. NHEKs grew in discrete colonies 
from the HDFs and MSCs. Data are representative of at least 3 replicates. 
 
The ECM deposition profile of the direct co-cultures are illustrated in Fig. 28. Col 
VII deposition is highly enhanced by co-culturing NHEKs with HDFs and MSCs. 
The deposition of Col VII was also more enhanced at the inferred borders between 
the mesenchymal cell types and NEHK cell clusters. Co-location between Col I 
staining and Col VII can be observed at 40X magnification.  
 
The deposition of Col IV and lam 3,3,2 too mirrored that of Col I and Col VII with 
the legit borders between the mesenchymal cell types and NHEK cell cultures seeing 
the most deposition. Again, the staining for the two ECM components when overlaid 
showed many areas of co-location. Interesting of note, was that the Lam 3,3,2 
staining pattern inside the NHEK clusters were that of less motile NHEKs (in rosette 
pattern) while the lam 3,3,2 staining on the outside of the clusters were that of more 




Fig. 28: Immunostaining for Col I, IV, VII and Lam 3,3,2 in NHEKs cocultured with HDFs or 
MSCs. Co-location at the borders of cell types can be observed in both sets of staining. This is 
indicative of an organized deposition of basement membrane related ECM proteins at the 
borders between NHEKs and the mesenchymal cell types. The deposition of ECM proteins in 
HDFs and MSCs cocultured with NHEKs appeared to be highly similar. Data are 





In this chapter, the ECM secreted by MSCs were evaluated. First, the ECM secretion 
profile of MSCs was studied. In order to simulate wound conditions, MSCs were pre-
activated with wound cytokines TGF-β and TNF-α for 24 hours (in the way cytokines 
wound peak in short intervals in a wound healing situation) before allowing them to 
deposit ECM proteins over a three day period. Skin related ECM proteins: Col I, Col 
III, Col IV and FN deposition were evaluated under different pre-activation 
conditions. Two functional assays were then used to see how these various ECM 
matrices would in turn influence keratinocyte proliferation and motility. The ECM 
deposited by MSCs when in direct contact with skin epidermal keratinocytes were 
also investigated for dermal-epidermal junction related ECM proteins. As dermal 
fibroblasts are the incumbent producers of ECM in the skin, they are used as a 
positive control in which we benchmark the deposition by MSCs.   
 
Macromolecular crowding (MMC) is a technique that attempts to mimic the crowded 
environment of biological systems [218] and our laboratory have shown that in the 
presence of MMC, we see an increased amount of ECM deposition in a shorter time 
period. I hence used the technique in our series of experiments to facilitate ECM 
deposition for analysis in a shorter time. This allowed me to shorten the ECM 
deposition time from 7 days as described by Chen et al to just 3 days [217].   
 
3.4.1 MSCs have fairly similar ECM deposition profiles as HDFs but may encourage 
wound healing more when pre-activated by wound cytokines 
MSCs have fairly similar ECM profiles as HDFs when non-activated. The similarity 
in ECM type secretion was briefly mentioned by Chen in a review paper [222]. 
However, MSCs produced a lot more in amounts of Col I and Col IV (Fig. 11 and 




What however was differentiating, was MSC's response to wound cytokines. TGF-β1 
is secreted in two phases during wound healing. Immediately after wounding, 
platelets release large quantities of TGF-β1 to kick start the inflammatory phase by 
attracting neutrophils. At the later stages of wound healing, TGF-β1 is accredited for 
the transformation of fibroblasts into myofibroblasts to contract the wound. When 
pre-activated by TGF-β1, HDFs increased Col I, IV and FN secretion, but Col III 
secretion appeared unchanged compared to non-activated HDFs. The increase in 
ECM secretion is in accordance with what was recorded in literature [223-225]. 
MSCs on the other hand, while also seeing increased Col I and IV did not see changes 
in FN deposition. This is probably because the FN levels were already saturated in 
MSCs. MSCs however saw a dramatic increase in Col III when pre-activated by 
TGF-β1 (Fig. 12 and Fig. 14).  
 
TNF-α is an inflammatory cytokine secreted by macrophages in the early stages of 
wound healing, its presence indicates to cells that there is a state of inflammation. 
HDF responds to TNF-α stimulation with a slight increase in Col I that decreases with 
concentrations of TNF-α and a slight increase in Col III. The increase in Col I is in 
accordance with what Duncan et al reported that showed an increase in Col I 
production under the influence of TNF-α in serum-free media [226]. Mauviel et al. on 
the other hand showed a decrease in collagen synthesis under the influence of TNF-α 
that's confirmed by proline incorporation and mRNA analysis [227]. They however 
did their experiment in serum containing medium, and Duncan et al showed in their 
study that the presence of serum may introduce unknown stimulatory effects on the 
cells due to the rich amount of growth factors present in serum. MSCs on the other 
hand, showed a decrease in Col I secretion when pre-activated by TNF-α (Fig. 11). 
The decrease in Col I was accompanied with an increase in Col III. This result in a tip 
of the balance between the ratio of Col III and Col I more than that of HDFs when 
pre-activated by TNF-α.  
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Col III is interesting for wound healing because it is related to fetal healing [228]. 
Mice diminished of Col III also have been shown by Volk et. al. [229] to have 
increased myofibroblast populations and scarring in cutaneous wounds. Prolonged 
TGF-β1 is related to scarring due to its ability to transform fibroblasts into 
myofibroblasts [99,230] while MSCs are suggested to reduce scarring most probably 
through paracrine secretion of factors such as HGF [231]. Our findings suggest that 
MSCs may also contribute to reduce scarring through increasing the Col III content in 
TGF-β1 rich wounds to diminish myofibroblast formation and hence improve on 
scarring results.  
 
Col III secretion and deposition by MSCs appeared to be highly dependent on by the 
passage number of the cells. In Fig. 12, I used donor MSCs obtained fresh from NUH 
at a passage number of P6-7, in Fig. 20 however, I used P9 human marrow derived 
MSCs purchased from Lonza. The Col III content dropped dramatically in 3 
passages. This similar effect of passage numbers affecting MSCs have been shown by 
Nakamura et al. where they recorded decrease in collagen and laminin content in 
murine MSCs with culture time [232]. This data suggests that MSCs used for wound 
healing applications should be as young in passage as possible to allow for maximum 
benefits from the treatment. In view of this, NUH cells at P6-7 were for the later 
functional assays.  
 
A decrease, though not statistically significant, in Col IV deposition by MSCs in 
response to TNF-α was also observed. Col IV is a basement membrane related ECM 
protein that can be broken down by MMP2 and 9. Ries et al. reported a dramatic 8000 
fold increase in MMP9 mRNA expression and some increase in MMP9 via 
zymography of MSC media after TNF-α stimulation [8]. Increase in MMP secretion 
into the matrix may be the cause for a decrease in Col IV deposition by TNF-α pre-
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activated MSCs. Whether MSCs downregulate Col IV expression too however needs 
to be examined with RT-PCR mRNA analysis.  
 
3.4.2 NHEKs seeded on decellularized ECMs have differential proliferation and 
motility responses.  
I wanted to know how secreted ECM from the HDFs and MSCs may affect NHEKs 
in the absence of cell-cell interaction and did so by deceullularizing the cell layer off 
cellular components and seeding NHEKs on them. Decellularizing matrices may 
cause loss in the deposited ECM. Col I and Col IV seemed to be unaffected for both 
cell types. Some fibronectin is lost due to the lysis protocol. More fibronectin was 
lost in HDF ECM compared to MSC ECM. This suggests that ECM produced by 
MSC are more stable than ECM produced by HDF. This however, needs to be 
validated through examination of crosslinking protein activity such as that of 
transglutaminases.  
 
NHEKs appeared not to be affected by the amount of ECM it was seeded upon, but 
instead the type of matrix they were seeded on. TGF-β1 pre-activated HDFs and 
MSCs alike had an inhibitory effect on the proliferation of NHEKs as observed in 
both the alamar blue assay and picogreen assay. This is probably at least partly due to 
an autocrine effect TGF-β1 has on fibroblasts [233]. Despite washing off the 
exogenous TGF-β1 after 24 hours, the pre-activated mesenchymal cells may have 
secreted additional increased amount of TGF-β1 into their matrices. TGF-β1 have 
been reported to be inhibitory to NHEK proliferation through suppression of the c-
myc transcription [234,235]. Nevertheless, the presence of TGF-β1 in decellularized 
matrices will need to be confirmed with further western blot or antibody staining.  
 
It was also found that decellularized matrices from TGF-β1 pre-activated MSCs 
caused a decrease in metabolic activity in NHEK cultures after 7 days that was not 
81 
 
observed in NHEK cultures seeded on decellularized matrices from TGF-β1 pre-
activated HDFs. DNA count on these MSC matrices were significantly lower than 
that of HDF matrices and this trend was observed in at least 2 repeats. Interestingly, 
when a salt wash was done on the ECM in order to release the ECM of growth factors 
and cytokines tethered ionically to it, there appeared to be a partial revival of the 
matrix's ability to support NHEK proliferation such that the amount of cells after 7 
days of culture on the TGF-β1 pre-activated MSC decellularized ECM were not 
significantly different from that cultured on similarly treated HDF ECM (data not 
shown). This suggested that MSCs either secreted more autocrine TGF-β1 or there 
exists a different NHEK proliferation inhibitor.   
 
TGF-β1 is a chemoattractant to NHEK migration and was reported to release 
keratinocytes' cell-cell interaction allowing them to be more motile [236,237]. Hence 
it is not surprising that NHEKs seeded on decellularized ECM secreted by TGF-β1 
pre-activated HDF had increased motility compared to that from non-activated or 
TNF-α pre-activated HDFs. However, NHEK seeded on decellularized matrices 
secreted by MSCs had high motility regardless of whether it was non-activated or 
pre-activated by TNF-α or TGF-β. The motility of NHEK in all three conditions were 
not significantly different from each other. This is surprising as proliferation and cell 
mobility are often views as one or the other events in cell biology. The NHEKs that 
were seeded on MSC deposited ECM (under all three states of pre-activation) appears 
to be performing both proliferation and motility functions at the same time.  
 
Keeping in mind that TGF-β1 has an inhibitory effect on NHEK proliferation, MSC 
matrices should have a separate stimulator to NHEK motility and proliferation that is 
not linked to TGF-β1. Some of the possible candidates are EGF and HGF. EGF is a 
potent stimulus for keratinocyte proliferation and motility [238,239] while HGF have 
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been shown to be secreted by MSCs [240,241] and were reported to promote 
keratinocyte cell motility but inhibit its proliferation at low Ca2+ conditions [242].  
 
Apart from matrix bound cytokines, ECM proteins may also be possible causes for 
the differences in NHEK behavior on the different matrices. A closer examination on 
the time-lapsed microscopy video of keratinocytes seeded on the various matrices 
showed that fibrillar structures in the ECM induced a migratory path for the NHEKs. 
The movement of NHEKs on TGF-β1 pre-activated MSC ECM also appeared to 
cover more displacement than NHEKs seeded on ECM secreted by MSC pre-
activated by TNF-α and non-activated. Those NHEKs appeared to move more around 
more in a fixed vicinity. Different ECM components were reported to have different 
effects on NHEK motility: Col I, III, IV, FN and Lam 3,3,2 appeared to increase 
keratinocyte motility while Lam 1 has been shown to inhibit it [243,244]. I showed 
that MSCs deposited more Col I, IV and FN indicating that there would be more 
adhering spots present for the cells. The structure and organization of the various 
ECM proteins in the ECM may also play a part in determining the NHEK path or 
motion.  
 
Further studies would be necessary in order to decipher which factor might have been 
decisive in determining NHEK proliferation and motility. However, our studies 
showed that MSCs secrete a slightly different ECM profile from the standard foreskin 
fibroblast and these differences were sufficient to allow MSC deposited ECM to 
promote keratinocyte movement and proliferation in a simulated wound environment. 
The migration of keratinocytes cultured on MSC deposited ECM compared to HDF 
deposited ECMs was observed to be significantly higher, both when non-activated or 




3.4.3 MSCs interact with NHEKs in a dermal-epidermal interaction-like manner 
Dermal-epidermal junction (DEJ) formation involving Col VII is a unique process to 
the skin that can be observed only when dermal fibroblasts were cultured in direct co-
culture with NHEKs [43]. There were several reports involving the use of MSCs in 
the treatment of dystrophic epidermal bullosa, a genetic disease that involved the lost 
of Col VII anchoring fibers. MSC have been reported to help replenish Col VII in 
human and mice subjects at least temporarily [245,246]. I was interested to 
understand if MSCs are capable of interacting with keratinocytes to form DEJ-like 
structures.  
 
Fig. 25 shows that all three cell types, HDFs, MSC and NHEKs do not produce all of 
the four DEJ related ECM proteins when cultured on their own. In direct co-culture, 
HDFs and NHEKs as well as MSCs and NHEKs do not mingle, instead, I see distinct 
islands of NHEK cultures with a mesenchymal cell background (Fig.27). This pattern 
is consistent to conventional keratinocyte cultures on mouse fibroblast (3T3) feeder 
layers and is consistent with what Omoto et al reported [247]. Further probing of the 
system with DEJ related ECM antibodies revealed that MSCs are able to produce 
similar DEJ-like ECM protein deposition patterns as HDFs. This finding suggests that 
MSCs are able to participate in cell-cell interactions with NHEKs in similar ways as 
HDFs to allow for the deposition of DEJ related proteins at specific junctions 
(borders between NHEKs and the mesenchymal cell types). However, when MSCs 
were used instead of HDFs in a collagen gel organotypic culture system 
(Supplementary 2), it appears as though MSCs do not support terminal differentiation 
of NHEKs in similar ways as HDFs. The cells on the upper layers of the stratified 
NHEK layer in MSCs supported organotypic cultures appear to not undergo the 
typical denucleation and granulation process like NHEKs seeded on HDF populated 
collagen gels [248]. Similar organotypic results were reported by Laco et. al. [249]. 
Schneider et al. [250] however suggested that MSCs will need to be embedded in a 
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suitable collagen matrix in order to achieve fibroblast-like dermal epidermal 
interactions. Our results suggest that MSCs can interact in similar fashions as HDFs 
when cultured in direct co-culture with keratinocytes in order to contribute to DEJ-
related matrix secretion.  
 
3.5 Conclusion 
In this chapter, I examined the hypothesis that MSCs can secrete ECM that modulate 
the wound healing process. I showed that MSCs are strong ECM secretors and their 
different ECM secretion profile from HDFs might adjust the ECM protein ratio in a 
wound environment. Functional assays on decellularized ECMs deposited by MSCs 
showed that the ECM support NHEK proliferation. When MSCs were pre-activated 
by TGF-β1, the ECM deposited inhibits NHEK proliferation like that of ECM 
deposited by HDFs that were similarly pre-activated by TGF-β1. MSC deposited 
ECM were very strong stimulants to NHEK motility compared to HDF deposited 
ECMs and this property may be one of the major factors how MSCs assist wound 
closure. I also demonstrated that MSCs were able to have dermal-epidermal 
interaction-like communication with NHEKs to produce skin specific DEJ-related 
ECM deposition, further confirming MSCs' role in modulating the ECM 




Cytokine functionalized scaffold - 
fabrication and characterization 
 
4.1 Introduction 
In addition to the various paracrine effects of MSCs, my work in the previous chapter 
suggests that MSCs can contribute to wound healing by secreting ECM that are 
conducive to wound healing. Chapter 2, Section 10 described how both endogenous 
and exogenously injected MSCs may home to the sites of injury in a natural process. 
The process is however not efficient with most of the exogenously infused cells 
filtering out in the lungs, liver and spleen [153,251]. As a consequence, cell therapy 
has to be administered in large numbers systemically or locally. Delivery of cells 
using a system like a hydrogel or a tissue engineered scaffold can help to partially 
circumvent the problem by providing a supporting substrate for cell adhesion [252]. 
They can also help to improve on cell viability when introduced into a harsh wound 
environment [11]. It would hence be an attractive strategy to introduce MSCs directly 
into the wound using a supporting scaffold. In this chapter, I describe the fabrication 
and functionalization of a construct to enhance and by-pass the natural homing of 
MSCs 
 
Nanomaterials are highly valuable in biomaterials as they are in the same size scale as 
the natural extracellular matrix of the body. In particular, electrospun scaffolds have 
excellent cell attachment properties due to their biomimetic resemblance to the 
natural collagen matrix [253]. Chan et. al. [254] showed that cells seeded on 
electrospun nanofibrous scaffold adhered faster than cells seeded on glass. Rapid and 
secure cell adhesion properties makes nanofiber membrane attractive as a substrate 
for cell delivery in the proposed system.  
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Due to its many advantages, I chose to make an electrospun scaffold that consist of a 
blend of a biological polymer (collagen) and a synthetic polymer (Poly-glycolic-co-
lactic acid, PLGA). This will allow us to combine the property strength of PLGA and 
the cell adhesive quality of collagen.  
 
Collagen serves as structural framework for the skin and is an essential bulk 
component of the natural ECM. It is an attractive biological material that contains a 
large number of  cell adhesion motifs that helps cell adhesion [255,256]. Collagen is 
naturally biodegradable and have low antigenicity due to its structure being highly 
conserved in evolution [257]. The collagen used in tissue engineering are usually 
atelocollagen derived from natural skin (bovine or rat tail) by solubilization using 
proteases. Atelocollagen is collagen without its structural crosslinks. They are soluble 
in acid and can be processed easily into a series of structures such as films, sponges 
and gels. However, atelocollagen is relatively weak mechanically and will degrade 
rapidly when implanted.  
 
In order to increase the strength and lifespan of the scaffold, PLGA was blended with 
collagen. PLGA is a synthetic polymer that is recognized as a biocompatible material 
used in a number of FDA-approved biodegradable sutures for various indications, 
including use in skin [258]. It is commonly used in the field of tissue engineering due 
to its tunable degradation properties, strong mechanical strength and non-toxic 
degradation products (lactic acid and glycolic acid). A combination of these two 
polymers have been previously used for fabricating skin tissue engineered scaffolds 
with favorable results [160].  
 
I then aimed to further improve the properties of the scaffold by introducing a 
combination of tissue modulating small molecules. Many groups had previously 
attempted to incorporate single growth factors [119], antibiotics [121] and drugs 
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[122] into their tissue engineering approaches, achieving encouraging results. 
However, wound healing is a complex mechanism involving cells, ECM, enzymes 
and growth factors. It is well established in biology that a cocktail of biochemical 
cues would be necessary to best enhance stem cell differentiation [135]. It would 
hence be logical that a combinatory approach to biochemical cues will have a 
synergistic effect on wound healing.  
 
Previously in our laboratory, Ma et al. [259] found that by using an induction medium 
that was optimized from Rheinwald and Green's keratinocyte expansion medium, 
they were able to increase the percentage of pancytokeratin expressing MSCs. They 
also showed establishment of a multi-layered epidermis-like structure when MSCs 
were cultured using this optimized induction medium on a contractible fibroblast-
embedded collagen gel with an air–liquid interface. Unfortunately, the induced MSCs 
were not verified for keratinocyte functionality with assays such as the expression of 
tight junction proteins and loss of nuclei with terminal differentiation and formation 
of highly reproductive holoclones [260]. Nevertheless, the cocktail comprised of 
factors that are wound modulating. They are: Vitamin C (Vit C), Hydrocortisone (H), 
Insulin (I), Triiodothyronine (T3) and Epidermal Growth Factor (EGF) (hereby 
known collectively as CHITE).  
 
Vit C application to burn wounds in mice has led to an increase in the synthesis of 
collagen, hexosamine, DNA, nitric oxide. Proliferation of fibroblasts and an increased 
vasculature in the wound bed was also observed [261]. Hydrocortisone is a known 
treatment for burn patients as it induces vasoconstriction, resulting in reduced 
capillary pressure. This limits edema and hence induces interstitial fluid to be 
reabsorb from non-burn areas [262]. Hydrocortisone has also been shown to improve 
vascular reactivity in sepsis [262]. Insulin helped to speed up the healing in burn 
wounds as it attenuates the inflammatory response by decreasing the pro-
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inflammatory, increasing the anti-inflammatory cascade and thereby restoring 
systemic homeostasis [263]. Insulin was also shown to increase the metabolism of 
glucose in burn wounds and increase matrix formation in repairing wounds [264]. T3-
treatment has been observed to aid in better quality wound healing i.e. better 
organized collagen bundles, fewer retraction spaces and smoother scars for rats with 
deep dermal burn [263]. EGF, when topically applied to burn wounds, has also 
showed enhancement in epithelialization as it is vital for collagen formation, 
epithelialization and granulation tissue formation [263]. Due to their various wound 
modulating properties, these factors were chosen to be blended into the scaffold in 
order to enrich its properties.  
 
In this chapter, I showed that by including a protectant protein (albumin), the 
bioactivity of the added biomolecules were conserved. The scaffold was further 
characterized for morphology, shrinkage properties, mechanical strength as well as 
release and degradation profile. CHITE released from the scaffold were able to 
increase the proliferation of skin cells (fibroblasts and keratinocytes) and maintain the 





4.2 Materials and Methods 
4.2.1 Fabrication of nanofibers via electrospinning 
Poly (DL-lactide-co-glycolide) (PLGA 75:25) copolymer at a molecular weight of 
90,000 to 126,000 (Sigma-Aldrich, Singapore) and Bovine Atelocollagen powder 
(Cosmobio, Japan) were mixed at a ratio of 1:1 (w:w) overnight at room temperature 
at 10% (w/v) concentration in 1,1,1,3,3,3-hexafluoro-2-propanol (HFP). Prior to 
electrospinning, biomolecules was added at their respective concentrations (see Table 
1) into 3.3% (w/v) of bovine serum albumin (BSA) (Sigma-aldrich, Singapore) in 
phosphate buffered saline (PBS). L-Ascorbic Acid Phosphate Magnesium Salt (Vit C) 
was purchased from WAKO, Japan. Hydrocortisone, Insulin, 3,3,5- Triiodo-L-
thyronine sodium (T3) and Epidermal growth factor (EGF) were purchased from 
Sigma-Aldrich, USA.  This cocktail of biomolecules (hereafter termed as the CHITE 
cocktail) were added according to Table 5 into the PLGA-collagen solution was then 
was then vortexed and ultrasonicated for 20mins on ice before placing the mixture in 
a plastic syringe which was attached to a 27 1/2 G needle. With the aid of a syringe 
pump (KD-Scientific, USA), the solution was dispersed at a feeding rate of 0.5 ml/h 
at humidity of 50% to 60% and temperature of approximately 24ºC. Electrospinning 
voltage was applied to the needle at 12-kV DC, using a high voltage power supply 
(Gamma High Voltage Research, Ormond Beach, FL). The electric field generated by 
the surface charge caused the solution drop at the tip of the needle to distort into a 
Taylor cone. Once the electric potential at the surface charge exceeded a critical 
value, the electrostatic forces would overcome the solution surface tension and a thin 
electrified jet of solution would erupt from the surface of the cone. The resultant 
CHITE-PLGA-Collagen scaffold (hereafter termed simply as CHITE scaffold) was 
collected on aluminum foil plate located 8 cm from the needle tip. Electrospinning 
was carried out for 2-3 hours depending on the amount of scaffold needed. After 
solvent evaporation, the CHITE scaffold coated aluminum foil was placed in a 
vacuum desiccators overnight to allow the evaporation of any remaining HFP solvent. 
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Blank scaffolds would be fabricated with the same procedure except that 3.3% (w/v) 
of BSA in PBS would be added alone without any additional biomolecules. 
 
Table 5: Compositions of CHITE loaded into PLGA-Collagen nanofibrous scaffold 
 
Composition of CHITE Mass per mg of fiber / ng  
C- L-Ascorbic Acid 
Phosphate Magnesium Salt  
9629 
 
H- Hydrocortisone 70 
I – Insulin 870 
T-3,3’,5-Triiodo-L-thyronine 0.12 
E- Epidermal growth factor 1.74 
 
4.2.2 Scanning electron microscopy 
Scanning electron microscopy (SEM) micrographs were obtained with JSM- 5800LV 
or JSM- 6510 scanning electron microscope (JEOL, Tokyo, Japan) or AURIGA FIB-
SEM (Carl Zeiss Microscopy, Jena, Germany) to observe the morphology of 
electrospun nanofibrous membrane. The diameter range of the fabricated nanofibers 
was measured on the basis of SEM images, using image analysis software (ImageJ, 
n=300). 
 
4.2.3 Mechanical testing 
Tensile tests were carried out in accordance to ASTM: D3039/D3039M (Std. Test 
Mthd. for Tensile Properties of Polymer Matrix Composite Materials) with a 5848 
microtester (Instron, Norwood, MA) at a stroke rate of 1 mm/min and with a 10-mm 
gauge length. Scaffolds tested were bone shaped with a width of 4 mm and a length 
of 20 mm.  
 
4.2.4 Differential Scanning Calorimetry (DSC) 
DSC measurements were carried out with a Mettler Toledo DSC1 instrument in a 
nitrogen environment. 0.6 mg of pure PLGA/collagen sample were hermetically 
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sealed in an aluminum pan for the measurements. Typical temperature profiles for the 
DSC study were as follows. The samples were heated from 0 to 100 °C at a rate of 
20 °C/min, held at 100 °C for 1 min, and then cooled to 0 °C at the same rate. 
 
4.2.5 Release profile determination 
Approximately 10 mg CHITE scaffolds were completely incubated in 5 mL of release 
buffer comprising of PBS with 0.1% BSA at 37oC over 7 days in falcon tubes, shaken 
at 100rpm. After specified intervals of 0.5, 2, 4, 8, 12, 24, 36, 48, 72, 144, 210, 312 
hours, all the release-medium was collected and fresh release medium was replaced. 
The kinetics of Vitamin C released from scaffolds was analyzed by Cayman 
Ascorbate Assay Kit 700420 (Cayman Chemical, USA); kinetics of Hydrocortisone 
by Cortisol ELISA kit (R&D Systems, Minneapolis, USA); kinetics of Insulin by 
Insulin (Bovine) ELISA (ALPCO Diagnostics, Salem, NH); Kinetics of T3 by T3 
ELISA (Calbiotech, Spring Valley, CA); kinetics of EGF by Quantikine Human EGF 
(R&D Systems, Minneapolis, USA). 
 
4.2.6 Degradation studies of scaffold 
Blank scaffold were fabricated as described in section 2.1, on 15 mm diameter cover 
glasses. The weight of fibers on each cover glass in approximately 1.2 mg and cut 
into shape. Sides of the scaffolds were glued to the cover glass to prevent scaffold 
movement using a medical grade silicone glue (Bluestar Silicones, Lakeside, USA). 
The scaffolds were then placed into 24 well tissue culture plates (Cellstar, Greiner 
Bio-one, North-America) and ethylene oxide (ETO) sterilized. After sterilization, the 
blank scaffold were soaked in 10% fetal bovine serum supplemented scaffolds and 
incubated in a 37°C sterile humidified incubator with 5% CO2. 
 
At day 1, 4, 7, 10, 13 and 16, the cultures were taken out and fixed with 4% 
methanol-free neutral buffered formaldehyde at room temperature for 20 min. The 
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samples were then washed with water and allowed to dry-up in a dry box. When 
completely dried, the samples were sputter coated with gold and imaged using a 
scanning electron microscope (SEM, Zeiss, Germany). 
 
4.2.7 Cell Culture 
HDF were purchased from ATCC (Manassas, VA, USA) and expanded in HG 
DMEM media supplemented with 10% FBS, 100 IU/ml penicillin and 100 μg/ml 
streptomycin (GIBCO, Invitrogen Corporation, USA) until ready for use. Cells at 
passage 8-9 were used for the studies. NHEK (adult, pooled) were purchased from 
Promocell (Heidelberg, Germany) and expanded in low calcium keratinocyte growth 
medium 2 (KGM, Promocell) until ready for use. Cells are passage +4 to +5 were 
used for the studies. Cells were incubated under standard culture conditions of 37°C 
in a sterile humidified incubator with 5% CO2. 
 
4.2.8 Bioactivity Assays 
Bioactivity assays were performed based on factors released from UV sterilized 
scaffolds. During the assays, weighed scaffolds loaded with only the single tested 
factor was added into transwell inserts (Greiner ThinCert™ 24 well, 0.4µm pore size, 
Greiner Bio-one, North-America; Transwell®-96 (HTS 8.0μm Pore Polyester, 
Corning, NY, USA) and lowered into cells cultured in test medium. The pores in the 
transwell will allow the released factor from the scaffold to diffuse and reach cells 
grown on the bottom of the culture wells. Culture media containing corresponding 
amount of loaded factors was added in wells containing blank scaffold as a positive 
control and blank scaffold in test media served as a negative control.   
 
Bioactivity of Hydrocortisone and T3 
Reporter assays (Indigo Biosciences Inc., PA, USA) were used to measure the 
bioactivity of hydrocortisone and T3 and used as instructed by the instruction manual. 
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These systems use non-human mammalian cells engineered to provide constitutive, 
high expressions of either Human Glucocorticoid Receptor (GR) (NR3C1), Human 
Vitamin D Receptor (VDR) (NR111) or Human Thyroid Hormone Receptor Alpha 
(TRα) (NR1A1). The cells incorporate either a GR, VDR or TRα ligand-dependent 
transcription factor, which in turn leads to a GR, VDR or TRα receptor responsive 
luciferase reporter gene being activated. Upon activation, the reporter protein 
Luciferin is transcribed. Addition of luciferase catalyzes the oxidation of luciferin 
resulting in the production of luminescence that can be quantified with using a 
Pherastar Microplate reader (BMG LABTECH GmbH, Germany). Quantifying 
expressed luciferase activity provides a surrogate measure of either GR, VDR or TRα 
activity in the treated cells and in turn allows us to determine if the biomolecules 
released from the scaffold are bioactive.  
 
UV sterilized scaffolds were loaded into Transwell®-96 that were loaded then into 
wells containing the respective reporter cells. Cell culture medium was loaded into 
the transwells to ensure that the NFS were completely submerged. The reporter cells 
were incubated with the NFS for no longer than 24hours, due to the short half-life (≤
1day) for T3, Hydrocortisone and VD3. 
 
Bioactivity of EGF 
The bioactivity of EGF was measured using a protocol adapted from Promega 
(Madison, USA) [265]. 10,000 HDFs per well were seeded in 24 well plates and 
allowed to adhere overnight in HDF expansion medium. Then, HDFs were serum-
starved in blank HG DMEM for 24 hours. Scaffolds containing 15 ng of EGF were 
then loaded in transwell inserts and lowered into the wells. After two days of 
proliferation HDFs were fixed in 4% methanol-free formaldehyde (10 min; room 
temp). Nuclei of fixed HDFs stained with 4', 6-diamidino-2-phenylindoldilactate 
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(DAPI) were counted using adherent fluorescent cytometry as previously described 
by Chen et al. [266] that was based on a montage of 9 sites per well taken by a 
coolSNAP HQ camera attached to a Nikon TE2000 microscope at 2x magnification, 
covering 56% of total well area and accessed with a single DAPI filter [Ex 
350nm/Em 465nm]. Images acquired of DAPI stained monolayers were then scored 
using an image analysis software (MetaMorph 6.3v3).  
 
Bioactivity of Insulin 
The preserved bioactivity of insulin was assessed in an MSC adipogenic 
differentiation assay using a standard induction cocktail lacking insulin but delivering 
this factor via the scaffold. MSCs (Lonza, p6) were seeded at an initial density of 
2.5x104 cells/well in 24-well plates (CellStar). Adipogenic differentiation was 
stimulated upon confluence via three cycles of induction/ maintenance, each cycle 
consisting of induction medium for 4 days (37°C, 5% CO2) followed by 3 days of 
culture in basal medium. During the induction cycle, transwells loaded with 
scaffolds containing 2 µg of insulin were lowered into each well. The induction 
medium is composed of HG DMEM supplemented with 10% fetal bovine serum, 100 
units/ml penicillin, 100μl/ml streptomycin, 3-Isobutyl-1-methylxanthine (0.5mM), 
dexamethasone (10-7 M), indomethacine (0.2 mM) with or without insulin (1.75µM) 
(Sigma-aldrich, USA). For the positive control, transwells loaded with blank 
scaffold were immersed in insulin (1.75 μM) supplemented induction media. 
For the negative control, transwells loaded with blank scaffold was immersed 
in insulin-deprived induction media.  
 
During the maintenance cycle, transwells containing the scaffolds were removed and 
the induction medium was changed to basal medium. The basal medium composed of 
HG DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 
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100μl/ml streptomycin. For the non-induced control, MSC were fed basal medium 
throughout both cycles.  
 
At the end of the three cycles of induction/ maintenance, monolayers in 24-well 
plates were rinsed with PBS, fixed in 4% methanol-free formaldehyde and stained 
with Nile Red (Sigma-Aldrich; 0.05mg/ml in water; 1hr), a fluorescent lysochrome 
specific for cytoplasmic lipid droplets and co-stained with 4',6-diamidino-2-
phenylindole (DAPI; 0.5μg/ml; 30min). 
 
Adherent fluorescent cytometry  as described in section 2.5.1 was performed. Nile 
Red was viewed under a single rhodamine filter [Ex 572nm/Em 630nm] while DAPI 
fluorescence was accessed with a single DAPI filter [Ex 350nm/Em 465nm] and 
using a method described by Ang et. al. [267], the extent of adipogenic differentiation 
was quantified by area of Nile Red fluorescence from threshold events then 
normalized to nuclei count based on detected DAPI fluorescence. End data 
correspond to total area of lipid droplets present per well relative to cell number.  
 
Bioactivity of Vitamin C 
HDFs were seeded in tissue culture dishes at a density of 50,000 cells/ 24 well plate 
well and allowed to adhere for 1 day in  HG DMEM supplemented with 10% 
FBS,100 units/ml penicillin and 100μl/ml streptomycin. On the second day, the 
culture media was changed to contain HG DMEM supplemented with 0.5% fetal 
bovine serum, 100 units/ml penicillin and 100μl/ml streptomycin, with or without 
100µg/ml of L-Ascorbic Acid Phosphate. Transwells loaded with either Vit C-
scaffold or blank scaffold immersed into the respective culture media. 
 
72 hours after loading the scaffold, the culture medium was pepsin digested to break 
down all protein contents except procollagen and the procollagen content was 
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quantified by sodium dodecyl sulfate polyacrylamide  gel electrophoresis (SDS-
Page). Triplicate protein samples were pooled and resolved under non-reducing 
conditions using in-house 5% resolving/3% stacking polyacrylamide gels on a Mini-
Protean 3 as outlined in Raghunath et al. [268]. Protein standard used were collagen 
type I standards from Koken Co. (Tokyo, Japan). Protein bands were stained with the 
SilverQuest™ kit according to the manufacturer’s protocol (Invitrogen, Grand Island, 
NY). Densitometric analysis of wet gels was performed on collagen α1(I) bands with 
a GS-800™ Calibrated Densitometer and Quantity One v4.5.2 image analysis 
software. 
 
4.2.9 CHITE Scaffold's Biological Effect on Keratinocytes and Fibroblasts  
The following protocol was used to test the biological effect of the eluted 
biomolecules on keratinocytes and fibroblasts:  
 
Primary keratinocytes or human dermal fibroblasts were seeded in expansion media 
at 10,000 cells per 24 well plate well and allowed to attach overnight. The next day, 
the cells were serum-starved in basal media (unsupplemented KGM for keratinocytes 
and blank HG DMEM for fibroblasts) for 24 hours. Transwells containing CHITE 
scaffolds (weighed so to contain the same amount of factors as that of 0.5 mL media; 
~3 mg) sterilized using ethylene oxide gas were then lowered into HDF or 
keratinocytes cultures in basal media. Negative controls contained blank scaffold. 
Positive controls contained blank scaffolds, which were immersed in medium 
supplemented with CHITE: 50 µg/mL ʟ-Ascorbic Acid Phosphate Magnesium Salt, 
0.4 μg/ml hydrocortisone, 5 μg/ml insulin, 1 nM T3 and 10 ng/ml EGF. 5 days later, 
the cells were lysed with a proteinase K, Triton X-100 buffer and its DNA content 





Cultures to be tested were taken out and lysed for 2 hours at 60 °C using a proteinase 
K buffer solution containing 1 mg/mL proteinase K (Sigma) in 10 mM Tris-HCl (pH 
8.5), 1mM Ethylenediaminetetraacetic acid (EDTA), 0.1% (v/v) Triton X-100. The 
lysis procedure breaks down the scaffold and cell membranes, releasing cellular 
contents including double stranded DNA, proteinase K action then breaks down 
proteins and enzymes leaving behind nucleic acids. The lysed cell solution was then 
assessed for double stranded DNA concentration (a direct indication of cell numbers) 
using Quant-iT™ PicoGreen® dsDNA Kit (Invitrogen Corporation, USA). The 
luminescent read-out was read using a spectrometric machine, Pherastar (BMG 
Labtech, Ortenberg, Germany). 
 
4.2.11 K10 staining for terminally differentiating keratinocyte cells 
Primary keratinocytes were seeded in KGM at 10,000 cells per 24 well plate well and 
allowed to attach overnight. The next day, the cells were serum-starved in basal 
media comprising either unsupplemented low calcium KBM or unsupplemented 
normal calcium 3 parts high glucose DMEM: 1 part Ham's F12 media (FAD media) 
for 24 hours. Transwells containing ETO-sterilized CHITE scaffolds were lowered 
into the keratinocytes cultures in KBM or FAD basal media. 5 days later, the cells 
were washed thrice with PBS and fixed with paraformaldehyde for 20 minutes. The 
cells were permeabilized with 0.25% Triton X-100 in PBS for 10 minutes and stained 
with mouse anti K10 primary antibody [clone DE-K10] (1:200) (ThermoScientific) 
and Alexafluor-594 secondary antibody. Five non overlapping random fields of view 
were taken per well using an Olympus epifluorescence microscope with DAPI as a 







4.3.1 Morphology of loaded nanofibers 
The scaffold was fabricated using blend emulsion electrospinning with bovine serum 
albumin (BSA) added as a protein protectant. Serum albumin is a common carrier 
protein used in drug delivery and was reported to enhance the stability and extend the 
half-life of peptide or protein based drugs in circulation [269,270]. Physiologically, 
serum albumin serves to bind and transport of important ligands such as fatty acids, 
metal ions, steroids, amino acids etc. [271]. The presence of sulphur containing 
amino acids, cysteine and methionine, in the structure of albumin confers albumin 
antioxidant properties. Albumin is also able to scavenge free radicals and function as 
a metal chelator to protect surrounding proteins from denaturation through oxidation 
[272].  
 
In the supplemented scaffold, a cocktail containing Vit C (C), Hydrocortisone (H), 
Insulin (I), T3 (T) and EGF (E) was used due to their proven efficacy in improving 
wound healing. However, it was found that upon addition of BSA into the organic 
solvent dissolved collagen-PLGA polymer mixture to form an emulsion, the resultant 
fibers were not uniform and contained beads ranging from 1 to 5 µm in diameter (Fig. 
29B). Fibers free of beads is important for ensuring even distribution of loaded 
factors within the scaffold so that there is consistent factor release. In order to ensure 
fine mixing of the emulsion, the spinning solution was dispersed by ultrasonicating in 
an ice-cooled water bath. The ice bath was used during ultrasonication to prevent heat 
generated during sonication from denaturing the added biomolecules. After 
ultrasonication, the resultant fibers were free of beads and had an average diameter of 







Fig. 29: A) Schematics of the fabrication of CHITE PLGA-collagen scaffolds. Blend 
electrospinning was employed where biomolecules consisting of Vit C, Hydrocrotisone, 
Insulin, T3 and EGF (CHITE) were mixed within the polymer solution of PLGA/Collagen 
(50/50) dissolved in HFP and then electrospun. In order to ensure uniform dispersion of the 
added biomolecules, ultrasonication was performed in an iced water bathe. The resultant 
fibers have an average diameter of 210 ± 62 nm (n=300). B) Scanning electron microscope 
(SEM) image of the BSA scaffold fabricated without ultrasonication, showing multiple 
irregularly sized beads. C)  SEM image of the BSA scaffold fabricated with ultrasonication to 
allow good mixture of scaffold components. The resultant scaffold was relatively bead-free 




4.3.2 Mechanical Properties of scaffolds 
The scaffold's tensile mechanical properties at room temperature were assessed using 
an Instron tensile tester. The scaffold had a breaking strain of 96 ± 10 % when dry 
and when wet, the elongation at breaking point increased to up to 117 ± 9 %. This 
places the strain at break of the scaffold on the upper range of that of normal human 
skin (35-115 %) [273,274]. The high strain at break indicates that the scaffold is a 
compliant and stretchable mesh. The pliability of the scaffold can be seen in the way 
the scaffold conformed nicely onto the contours of the wound. (Fig. 30C). When dry, 
the scaffold has an ultimate tensile stress of 2.8 ± 0.29 MPa and when wet, it is more 
fragile with an ultimate tensile stress of 0.6 ± 0.07 MPa. According to a surgeon who 
is familiar with skin grafts, the scaffold handles very much like a spilt thickness skin 
graft. Despite the low tensile strength, the scaffold can be handled without 





Fig. 30: A) Tensile mechanical analysis of the scaffolds dry and wet at room temperature. 
With a table collating the scaffold’s tensile modulus, ultimate tensile stress and ultimate strain. 
B) Photo showing the handibility of the scaffold – the scaffold can be held up using forceps 
even when wet. C) Photo showing the scaffold's ability to conform with the contours of the 




4.3.3 Scaffold Shrinkage & Differential Scanning Calorimetry (DSC) 
It was observed that the PLGA-Collagen scaffold shrinks significantly under 
physiological conditions (Fig. 31). A detailed quantification shows that when the 
mats were submerged in PBS at 37 oC, there is rapid shrinkage to ~24% its original 
size within the first 30 minutes. The scaffold shrank to 10% of its original size within 
the first 2 days.  The shrinkage in two dimension was observed to be identical in all 
directions while the thickness of the scaffold was observed to be increased over time 
even though the thickness not measured.  
 
This property of PLGA scaffold shrinking at physiological conditions was also 
observed by Zong et al. [275] who attributed it to the glass transition temperature of 
PLGA being decrease from 60 °C to a temperature near 37 °C by the process of 
electrospinning. Glass transition temperature is a temperature in polymer chemistry 
that above which, the polymer chains are more flexible and free to move around and 
below which, the polymer is brittle and hard. Indeed, the glass transition temperature 
of the electrospun scaffold was studied using differential scanning calorimetry and 
was found to be 41.39° C (onset). It was also observed that the presence of water is 
necessary to elicit a shrinkage of the scaffold. It is possible that water molecules that 
invaded the gaps between the polymer chains allowed greater freedom for the chains 
to move and return to their inherent elastic memory state where the chains were less 
stretched [276]. 
 
4.3.4 Degradation properties of scaffold 
The degradation properties of the scaffold were investigated by soaking scaffolds 
attached to glass coverslips in DMEM media supplemented with 10% FBS in a 37 °C 
cell culture incubator with 5% carbon dioxide to simulate physiological conditions 
(Fig. 32). The morphology of the degrading fibers were studied at fixed time points. 
The fibers of the scaffold appeared to have enlarged rounder pores one day after 
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soaking (Fig. 32, 20 000X image). This is probably due to uptake of liquid from the 
degradation buffer that will cause fiber swelling. By day 7, first holes appeared on the 
surfaces of the fibers, progressing into big crevices throughout the fibers by day 16 
and major loss of scaffold integrity. In fact, there was large loss of bulk of the 
scaffold observed indicating that significant portions of the scaffold had broken up by 
the 16th day.    
 
 
Fig. 31: Size of PLGA scaffold and PLGA-Collagen scaffold shown as a percentage of its 
original size in a wet state after a 48 hours direct immersion in PBS at 37oC (without 
overnight soaking at 4oC). Data represent the mean (n = 3), and error bars represent standard 






Fig. 32:: SEM Degradation profile of blank scaffold soaked in 10% FBS supplemented media 
for 1, 4, 7, 10, 13 and 16 days at 2000X and 20 000X magnification. The scaffold had bigger 
fiber diameter as compared to when dry 1 day post soaking, indicative of swelling due to 
liquid uptake. The scaffold had bigger and rounder pores after soaking. SEM images showed 
appearance of holes within the individual  fiber shaft of the scaffold starting from 4 days post-
soaking and degradtion continued progressively over 16 days. By the 16th day, there was very 
little bulk material left behind. 
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4.3.5 Release profile of scaffold 
The release profile of the CHITE scaffold was investigated by measuring the released 
cytokines using specific ELISAs for individual factors (Fig. 33). Total volume of 
release buffer was extracted at each time point and replaced with fresh buffer in order 
to simulate a sink environment. This is the release condition best comparable to in 
vivo conditions where the plasma half-life of the cytokines is only several minutes to 
hours [277]. Up to 97% of hydrocortisone and EGF was recorded to be released 
within 8 hours. T3 and insulin on the other hand achieved a total release of around 
80% during the period of our study. Vit C showed a slower controlled release of 
factors, releasing around 55% of its incorporated factors 4 hours into the study and 
another 35% in the next 4 hours.  
 
 
Fig. 33: Cumulative release profile of supplemented factors, CHITE over 48 hours. Release 
buffer was completely removed and replaced with fresh buffer at every time point in order to 
simulate a sink environment in the wound site. Factors exhibited a burst release profile with 
more than 80% of  the added factors released 12 hours post-soaking.   
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4.3.6 Bioactivity of factors 
A large number of factors with different characteristics were incorporated in the 
scaffold. It was crucial to ensure that all of them were able to withstand the harsh 
conditions of high voltage and organic solvents related to electrospinning and still be 
functional once released. Therefore the bioactivity of the individual incorporated 
factors was investigated. For this purpose either commercially available systems were 
used and in some cases novel read-out systems were established. Fibers containing 
only one factor of interest were used in each assay in order to ensure specificity of the 
read-out. A transwell system was used in the assays to ensure that only released 
factors, which diffused through the transwell membrane were measured. The results 
of the individual bioactivity assays tested were compiled in Fig. 34.  
 
Hydrocortisone and T3 were studied using a commercially available bioactivity assay 
kit from Calbiochem. The system uses transformed cells that will cause a luciferase 
gene to be transcribed when the factor of interest binds to specific receptors on the 
cells. As the luminescence detected was proportional to the concentration of the 
factor of interest in the medium, fresh factors added directly to the medium were used 
to calculate a calibration curve. Back calculation from the read-outs estimated that 
around 33% of the factors included in the fibers were released as bioactive molecules 
and could bind with their respective cell receptors. This yield of bioactive 
hydrocortisone and T3 was much higher than expected and demonstrates that the 
blend electrospinning method may be a reliable method to create bioactive scaffolds 
for tissue engineering applications.  
 
A well established bioactivity assay was used to determine the bioactivity of EGF. 
Due to the mitogenic effect of EGF, it was able to increase the proliferation of 
fibroblasts. However, the increase in cell proliferation is not directly proportional to 
EGF concentration. Therefore quantification of bioactive EGF was not possible with 
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this method. Nonetheless, EGF released by the scaffold was able to significantly 
increase the proliferation of HDFs 48 hours post stimulation. Therefore the released 
EGF was proven to be bioactive as well.  
 
Self-devised systems were used to investigate the bioactivity of Vit C and Insulin 
added into the fibers. It is known that Vit C is an important cofactor for prolyl 
hydroxylases that catalyses the post-translational hydroxylation of proline in 
procollagen. When added in cell culture, Vit C increases the in vitro secretion of Col I 
into the culture medium [218]. This characteristic of Vit C was made use of in this 
self-devised system using human dermal fibroblasts. Silver staining of SDS-page gels 
on pepsin digested samples that have all proteins except collagen digested, showed 
that there was increased collagen secretion in cells grown in the presence of Vit C 
containing scaffolds.  
 
In the investigation of functionality of insulin, a system that involves the 
differentiation of MSCs into adipocytes was used. Being a mesenchymal lineage 
progenitor, MSCs will differentiate down the fat lineage if given the right in vitro 
cues. Insulin is a common "ingredient" in the differentiation cocktail for adipogenic 
differentiation of MSCs and was previously shown to act through the IGF-I receptor 
[278-280]. This property of insulin was made used of in this assay system and 
increased fat droplet accumulation (nile red staining) was observed in MSC 
differentiated with insulin containing scaffolds.  
 
Despite of the use of organic solvent for dissolving the polymer portion of the 





Fig. 34: In vitro bioactivity assay of individual CHITE biomolecules released from scaffolds. 
Scaffolds containing single biomolecule type were tested for bioactivity. The biomolecule 
amount released from the scaffolds on the right most bars (black) represent the amount of 
biomolecules incorporated during electrospinning. All factors that were released were able to 
cause significant difference in cellular activity: vitamin C increased fibroblast collagen 
deposition; Hydrocortisone and T3 increased reporter cell luminescence protein expression; 
insulin increased lipid accumulation in adipogenesis of MSCs and EGF increased fibroblast 
proliferation. All factors were hence determined to retain bioactivity post scaffold fabrication. 
Mean (n = 3), error bars represent standard deviation and * indicated a one tailed student’s t-





4.3.7 Keratinocytes and Fibroblasts increase proliferation in respond to CHITE 
scaffold 
The response of keratinocytes and fibroblasts, local cells within a wound, was 
investigated in vitro by allowing the supplemented scaffold to release its contents 
while sitting in a transwell (Fig. 35). This is to emulate the wound situation where 
cells may not be in direct contact with the scaffold. 5 days post exposure to CHITE 
scaffold, both keratinocytes and HDFs registered significantly more cells per well 
then when exposed to plain scaffolds or no scaffold.  
  
 
Fig. 35: Proliferation assay of A) Primary keratinocytes grown in presence of CHITE scaffold, 
and B) HDF grown in presence of CHITE scaffold. Enhanced proliferation of both cell types 
was observed 5 days post exposure to CHITE scaffold. Mean (n = 3), error bars represent 





4.3.8 Keratinocytes maintained their stemness in respond to scaffolds.  
Keratinocytes exposed to the scaffolds were assessed for their differentiation state in 
keratinocyte growth media and it was observed that less cells expressed cytokeratin 
10 interfilaments (K10) in the presence of CHITE scaffolds as compared to in the 
presence of plain scaffolds (Fig. 36). K10 is a marker for suprabasal keratinocytes 
committed to terminal differentiation. As differentiated keratinocytes do not 
proliferate anymore, naïve keratinocytes are needed during would healing. The 
absence of K10 is a good indicator that CHITE scaffold supports a more naïve state 
of keratinocytes. Interestingly, when the assay was repeated in media containing 
physiological Ca2+, which induce terminal differentiation of keratinocytes, it was 
observed that the presence of any scaffold, with or without CHITE, suppressed the 
expression of K10. As previously shown, Picogreen DNA quantification showed that 
there was significantly more cells in the presence of CHITE scaffolds then plain 
scaffolds after 5 days of culture, suggesting that CHITE within scaffold supports 







Fig. 36: Keratinocytes seeded on tissue culture plate in low calcium, differentiation 
discouraging KBM with/ without CHITE scaffold over a period of 5 days. (left) 
Quantification of area of cytokeratin 10 (K10) staining (red) against DAPI staining (blue), 
(right) representative microscope images of keratinocytes (4X magnification) under different 
conditions. Similar assays were performed with A) keratinocyte basal media (KBM) that is 
low in calcium and formulated to maintain keratinocyte stemnes and B) Keratinocytes seeded 
on tissue culture plate in FAD media that was formulated to promote keratinocyte 
differentiation. K10 is a marker for keratinocytes committed to terminal differentiation and the 
marker expression was decreased under CHITE treatment. Blank scaffold on its own was able 
to prevent keratinocyte terminal differentiation. Cells exposed to CHITE showed increased 
proliferation as seen by DAPI nuclei staining. Mean (n = 3), error bars represent standard 





In this chapter, I aim to fabricate a nanofibrous scaffold meant for cell delivery that is 
bioactive and would modulate the local wound environment when introduced. 
Electrospun non-woven mats are relatively fuss-free to generate and offer attractive 
options for tissue engineering delivery systems. The method has various advantages 
including: flexibility of material choice that allows for material combinations for best 
efficacy; natural ECM-like architecture to facilitate cell attachment; high porosity, 
allowing for easy exchange or materials through the scaffold and most importantly, 
the option to load various cytokines and drugs to enhance the efficacy of tissue 
healing and regeneration (see Chapter 2). 
 
Electrospinning has also been streamlined with the use of machines such as the 
nanospider [116] to facilitate good manufacturing practice (GMP) grade scaffold 
fabrication. This will allow easy transfer of technology when the system is scaled up 
for industrial applications. The choice of using a blended emulsion of factors in 
organic solvent dissolved polymers eliminates the need for sophisticated apparatus, 
allowing the scaffold to be fabricated with relative ease and consistency irrespective 
of the handler. 
 
While tensile stress properties are of minimal importance for skin dressings, a ductile 
strain property will allow the dressing to conform to the contours and movement of 
the body minimizing disturbance to the mobility of patients. The ability of the 
scaffold to be held up without tearing with forceps also allows easy handling by 
surgeons.  
 
The degradative behavior of the fibers were indicative of bulk degradation with the 
scaffold maintaining its macroscopic structure for the initial days and a catastrophic 
collapse of fiber integrity after 16 days and most of the scaffold breaking down. In an 
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in vivo system, the scaffold is expected to degrade even faster with the presence of 
collagenases and metalloproteinases secreted by macrophages and phagocytes [281].  
The relatively rapid degradation behavior of the scaffold is suggestive that the 
scaffold will serve as an effective delivery system that would rapidly give way to 
migrating and proliferating cells after application.  
 
The scaffold was designed to provide a boost of growth factors at application. It was 
reported that skin wounds should be treated as soon as possible and a wound that does 
not display signs of closure after 4 weeks [282,283] will develop into a chronic 
wound. It is hence paramount for clinical interventions to be provided during the 
early stages of wound healing.  
 
The release profile of the CHITE scaffold was investigated in a submerged system 
using ELISAs for individual factors. A sustained release profile that plateau at around 
12 hours is observed. While this is relatively quick, long term stimulation of cells in 
the wound site with growth factors may not be necessary. As shown in Tan et al. 
[233], a 4 hours stimulation with TGF-β1 was as good as causing myofibroblast 
transformation/differentiation of fibroblasts as a 4 day stimulation due to an autocrine 
stimulation of TGF-β1 by fibroblasts after short pluses of external stimulation.  In the 
event when the scaffold is used in conjuncture with skin grafts or stem cells, as 
described in Chapter 1, the first hours post-transplant also will be most critical in 
maintaining graft health and take [284]. I believe that a system that provides major 
stimulation boost in the first hours post implant will be most efficacious. Short term 
release may also be better as a long term release of mitogenic factors have been 
related to malignant transformation in cells. A more physiological system of growth 




Concerns were frequently expressed over the functional bioactivity of factors 
included in blend electrospinning systems due to the direct contact of hydrophilic 
factors with organic solvents. Some have even designed special systems to overcome 
these short comings such as co-axial electrospinning [13,125] and post-
electrospinning conjugation [119]. I decided on a blend emulsion system for the 
scaffold due to the ease of fabrication. In order to partially circumvent the problem of 
lost of bioactivity of the biomolecules, BSA was used as a protector protein to help 
maintain the viability of the added cytokines. In the body, serum albumin also 
functions as a co-factor for various proteins and vitamins, enhancing their biological 
functions and it is used as a strategy to extend the half-life of antibodies and proteins 
[286,287]. While many groups have tested the viability of one or two growth factors 
in their controlled release systems [13,127], it is to my best knowledge that the 
bioactivity of so many different kind of cytokines released from a single system was 
tested. In this system, there is a water soluble small molecule vitamin (vit C), a 
steroid (hydrocortisone), one small molecule hormone (T3), one peptide hormone 
(Insulin), and a growth factor (EGF). These factors are susceptible to oxidation or 
denaturation to different extend. It was verified that all the included factors managed 
to withstand the relatively harsh processing conditions and maintained functionality 
in cellular assays. The percentage of added factors that were functional post-
processing was quantifiable as the luminescent assays used for determining the 
bioactivity of hydrocortisone and T3 gives quantitative data on the concentration of 
bioactive factors. Back calculations showed that around 37% of hydrocortisone and 
35% of T3 were functionally active for binding to their respective receptors (see 
Supplementary 3).  
 
When combined, the factors were tested using the two most major cell types in the 
skin: epidermal keratinocytes and dermal fibroblasts. The CHITE scaffold, despite 
having lost around 70% of its included factors, were sufficient to stimulate the 
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proliferation of keratinocytes and HDFs in a significant manner compared to plain 
non-supplemented scaffolds.  
 
It was also found that keratinocytes grown in the presence of CHITE scaffolds 
appeared had a more basal morphology. This observation was confirmed by the lack 
of K10 marker stain, an indication of the lack of terminal differentiation. Only cells 
that are committed to terminal differentiation express K10 markers [288]. 
Unsupplemented media containing no growth factors or serum were used to test the 
potency of the scaffold released factors. When nutrients are low, keratinocytes 
generally differentiate as a default response, any ability of the scaffold released 
factors to inhibit differentiation will indicate their bioactivity. The absence of K10 
staining in keratinocytes grown in the presence of CHITE indicates that the cells were 
not only proliferating faster, but they are also kept as a whole in a more proliferative 
basal state. The ability of CHITE to stimulate proliferation of skin cells is very useful 
in the initial stages of wound healing when keratinocytes and fibroblast from the 






In this work, a bioactive multi-component containing delivery system was fabricated 
with intentions to improve local cell proliferation and viability. Five biochemically 
distinct molecules were blended into an electrospun scaffold designed to be 
commercially viable in large scale production. The fabricated wound dressing was 
easy to handle, released factors in a controlled manner over 12 hours and had fast 
degrading properties to accommodate space needed for regenerating tissue. All of the 
five included factors were shown using comprehensive cell assays to be bioactive 
despite relatively harsh processing methods. The dressing was also shown to be able 
to improve the proliferation and maintain the proliferative capacity of local skin cells 
such as keratinocytes and fibroblasts. In conclusion, a highly potent biodegradable 
wound dressing for cell delivery that will stimulate local cell response in a skin 






Chapter 5:  
Design of a cell concentrating system 
and preliminary in vivo study   
 
5.1 Introduction 
Chapter 3 established how MSCs may contribute to wound healing through 
modulation of the microenvironment of a wound. An electrospun membrane that 
contains bioactive biomolecules in order to stimulate healing in the local wound 
environment was then engineered in Chapter 4. In this chapter, I devise a method for 
combining in situ MSCs with the electrospun scaffold described in Chapter 4. The 
system was then used in a preliminary in vivo study to test its efficacy in healing a 
splinted full thickness skin wound in a rat model.   
 
Traditional tissue engineering approaches involves first isolating the cells of interest 
from the patient then culturing them ex vivo until they reached therapeutic numbers. 
The cells would then be seeded onto scaffolds prepared for the targeted tissue and 
grown in vitro until ready for implantation (Fig. 37). The entire process from cell 
isolation to scaffold implantation may take up to 2-4 weeks. This waiting time period 
may cause physicians to miss the treatment window for best clinical results in 
severely wounded patients [15,16].  
 
In this design, I aim to eliminate the time needed for ex vivo cell culture and create a 
one-step in situ procedure to concentrate cells onto electrospun scaffold for use 
immediately, without any further culture, in the treatment of full thickness skin 





The cells to be used can be from two sources:  
1. freshly isolated autologous bone marrow cells (hereby by-passing the need 
for MSCs to home to the site of injury);  
2. allogenic pre-expanded MSCs.  
 
The cells will be concentrated on the bioactive cytokine functionalized electrospun 
scaffold using a self-designed system and applied directly onto the wound without 




Fig. 37: Schematic diagram showing the conventional tissue engineering approach. Reprinted 
by permission from Macmillan Publishers Ltd: [Nature Nanotechnology,  





Fig. 38: Illustration of the in situ skin tissue engineering system envisioned 
 
In this chapter, we have 2 aims:  
1. To devise a system for rapid concentration of cells onto the electrospun 
scaffold engineered in Chapter 4. 
2. To evaluate the efficacy of the MSC-bioactive construct when combined in 





5.2 Materials and Methods 
5.2.1 Scaffold fabrication 
The methods of fabricating the scaffold was discussed in Chapter 4. 
 
5.2.2 BMSC Early Attachment Assay 
Mononucleated cells isolated from pig bone marrow aspirates (obtained through the 
NUS tissue sharing programme) after red blood cell lysis (RBC lysis, see supplement 
2) were placed in a supporting ring on top of the nanofibrous mats and concentrated 
with a vacuum suction pump that sucks any residual fluid through the pores of the 
nanofibrous mat. The residual cell "cake" was then fixed with 4% paraformaldehyde 
and dried in a dry box for SEM imaging or stained with anti-pig CD 29 antibody or 
anti-human (with cross reaction with pig) CD 90 antibody (BD Pharmigen, CA, 
USA) for fluorescence microscopy. 
 
5.2.3 Solidworks drawing and 3D printing 
3D CAD drawings were made using SolidWorks (Dassault Systèmes SolidWorks 
Corp. , Waltham, MA, USA) and saved as .STL files for processing. The MakerBot 
Replicator (MakerBot, USA) was then used to 3D print out the prototypes using an 
ABS filament.  
  
5.2.4 Cell culture 
Human bone marrow-derived mesenchymal stem cells (MSCs) were purchased from 
Lonza (Basel, Switzerland). The MSCs were expanded in low glucose (LG) 
Dulbecco's Modified Eagle Medium (DMEM) media supplemented with 10% fetal 
bovine serum (FBS), 100 IU/ml penicillin and 100 μg/ml streptomycin (GIBCO, 
Invitrogen Corporation, USA) until ready for use. All cells for animal work were used 




5.2.5 Rat Wound Model 
The animal work was performed under the approval of the university's ethical 
committee (Institutional Animal Care & Use Committee [IACUC] ), protocol number 
R13-4864. 5 conditions were tested in the animal model with 3 replicates per 
condition:  
1) SHAM  
2) PS: Plain scaffold 
3) PSC: Plain scaffold + 2 million human BM-MSCs 
4) SS: CHITE scaffold  
5) SSC: CHITE scaffold + 2 million human BM-MSCs 
The splinted full thickness skin wound model was adapted from Gurtner's group's 
experiment on mice [292] in which skin edge was restrained from contracting to 




Fig. 39: Illustration of the splinted full thickness skin wound model  on a rat. MSCs were 
concentrated on the CHITE scaffold immediately before application onto the wound. 
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Rats were individually anesthetized using gaseous isoflurane (5%) until they were 
completely knocked out. They were then maintained on 1-2% isoflurane administered 
through a nose cone throughout the surgery. The dorsal surface was shaved with an 
electric clipper followed by a depilatory agent (Veet) to remove any remaining hair. 
The rats were rinsed with water and finally an alcohol swab to remove all residual 
Veet. The shaved area was sterilely prepped with betadine and draped. A sterile 10 
mm punch tool was used to outline a pattern for the wounds with methylene blue on 
the dorsum of the SD rats. A single wound slightly lower than the most caudal part of 
the scapula was patterned on the midline of the rat. Full-thickness wounds extending 
through the panniculus carnosus were then made using an Iris scissor. For rats 
undergoing treatment with the PLGA/collagen construct, a 15 mm diameter construct 
was then placed over the wound and held in place using 4 interrupted sutures 
(tapered, 5-0 Premilene sutures, BBraun, USA). If cells were to be seeded, 2 x 106 
human bone marrow derived mesenchymal stem cells were filtered onto the 
PLGA/collagen construct before application onto the wound. A donut-shaped splint 
with an outer diameter of 34 mm and an inner diameter of 14 mm was fashioned from 
a 0.5mm-thick silicone sheet (Grace Bio-Laboratories, Bend, OR, USA). The splint 
was centered over the wound. An immediate-bonding adhesive (Gel Super Glue; 3M, 
St. Paul, MN, USA) was used to fix the splint to the skin followed by reinforcement 
with four interrupted 6–0 Premilene sutures (BBraun, USA). OP-SITE spray 
(Smith&Nephew, USA) was applied to the splint to improve adherence of the 
occlusive dressing (Tegaderm, 3M, St. Paul, MN. USA) placed to cover the wounds. 
The animals were placed in individual cages on a warming pad and allowed to 
recover fully from anesthesia. The animals were housed individually in the 
university's animal facility with enrichments throughout the course of the study. 
 
The rats were given 48 hours of buprenorphine injections and 5 days of baytril 
injections post-operatively. Dressings were change whenever deemed necessary. All 
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rats were force fed tacrolimus daily (1mg / kg) as an immunosuppressant  from the 
day before their surgery to the end of the experiment to prevent rejection of the 
applied human MSC [160]. 
 
5.2.6 Wound analysis 
Digital photographs were taken the day after the surgery and every day thereafter. 
Wound area was analyzed by tracing the wound margin (Fig. 40) with a fine-
resolution computer mouse and calculating pixel area using ImageJ (NIH, USA). The 
analysis was repeated three times for each wound image. Because the splint has a 
constant area, it was used to normalize the wound sizes. Where the splint was not 
present, a ruler was placed on the wound and used instead.  
 
 
Fig. 40: Inclusion criteria for a closed wound. The yellow line represents the included wound 
size that was measured using ImageJ. The criteria of exclusion of wound area are: 1) colour 
similar to surrounding skin, 2) dry appearance.  
 
5.2.7 Histological stains 
The mice were euthanized the time of wounding. On day 15, the rats were sacrificed 
with carbon dioxide and the wounds were excised. The samples were bisected, and 
either fixed in 4% paraformaldehyde or flash-frozen in cryo-OCT. Histology work 
(embedding, sectioning and Masson Trichrome staining) was performed by the 
Advanced Molecular Pathology Laboratory, IMCB, A*STAR, Singapore. 
 The samples also underwent routine histological processing with hematoxylin and 
eosin and picrosirius red. The samples were then observed under brightfield 
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microscopy and polarized light microscopy (picrosirius red stained samples) and were 
photographed using a mounted digital camera (Olympus, Melville, NY, USA). The 
images were assembled into a whole mount image using (Fiji is Just)ImageJ after 
background correction using the pairwise stitching function plugin developed by 
Preibisch et al. [293]. 
 
5.2.8 Immunohistochemistry 
Fresh frozen samples were fixed with 4% methanol-free neutral buffered 
formaldehyde for 10 min at room temperature and then permeabilized with 0.25% 
Triton X-100 solution in phosphate buffered solution (PBS) for 10 min prior. Samples 
were blocked with 3% bovine serum albumin and incubated overnight at 4 °C with 
primary antibody. The primary antibodies used were Rb anti-human Ku80 [clone 
EPR3468] (ab80592, Abcam, USA) , Ms anti-human mitochondia [clone 113-1] 
(ab92824, Abcam, USA), Rb anti-pancytokeratin, wide spectrum screening (DAKO, 
USA) and Ms anti-alpha smooth muscle actin [clone 1A4] (DAKO, USA). An 
alexafluor-594 conjugated anti-rabbit antibody and highly crossed absorbed 
alexafluor-488 conjugated anti-mouse antibody (Life Technologies, USA) was then 
used to enable visualization. All stainings were counterstained with DAPI to enable 
identification of cell nuclei. The samples where then imaged using an epifluorescence 
microscope (Olympus, IX-71) and photographed using a mounted digital camera 
(Olympus, Melville, NY, USA). The images were assembled into a whole mount 
image using (Fiji is Just)ImageJ after background correction using the pairwise 






5.2.9 Wound edge measurement 
Samples stained with pancytokeratin, α-SMA and DAPI were used for wound 
epithelialization measurement. The method of mesurement used was described in Fig. 
41. The granulation tissue was identified by an area with no skin appendages (round 
pancytokeratin stained areas in the dermis). The epithelial gap was measured as the 
gap parallel to the skin that the epidermis did not cover. The percentage closed is then 
calculated from it using the formula described in Fig. 41.  
 
 





5.3.1 Concentration of cells onto the engineered scaffold 
The system described in Fig. 38 required a method to enrich cells onto the scaffold. 
Filtration is a fast and easy method of removing fluids while retaining objects bigger 
than a certain size. It is an ideal method of quickly concentrating cells onto porous 
membranes. Electrospun nanofibrous scaffolds are non-woven mats that are highly 
porous with small pores and can be used as cell filters [294]. Hence, I attempted to 
filter mononucleated cells onto the scaffold using the set-up shown in Fig. 42. Fig. 43 
shows an SEM image of cells concentrated on the surface of our electrospun 
nanofibrous membrane. The backside of the membrane was shown in Fig. 43 (right), 



















Fig. 43: SEM images of (left) cells filtered on to the nanofibrous membrane and (right) the 
back side of the nanofibrous membrane. 
 
5.3.2 Design of a compact filtrating system to concentrate cells onto the 
PLGA/collagen construct 
5.3.1 showed that filtrating the cells onto the PLGA/collagen construct is a feasible 
and efficient way to concentrate bone marrow cells (Fig. 42,43). I then brought the 
system further by designing a filtration system for use during my animal surgery. The 
system was used in conjuncture with a 10 mL syringe (cut) (Terumo, Japan), a 
Clearlink Luer Activated Valve connector (Baxter, Deerfield, IL, USA) and a soft 
polymer tube. A picture of the system used for the animal pilot run is shown in Fig. 
44 and a schematic drawing in Fig. 45. The system was printed using a 3D printer 
using ABS material and can be sterilized for use using ethylene oxide. The 10 mL 
syringe filter (Fig. 44 right) can be made disposable while the others are reusable as 





Fig. 44: Prototype of filtration system designed to concentrate BM-MSCs onto the 




Fig. 45: SolidWorks CAD drawing of (top) the filter system that fits into a Terumo 10 mL 
syringe and (bottom) the holder unit for easy filtration on the table top. 
 
Pull to create 
suction vacuum 
Place scaffold here 
Put isolated bone marrow cells here 
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5.3.3 Gross wound morphology and wound size measurements 
Rodents are attractive models for animal studies due to their easy handling and 
shorter healing times and generally less complications [295]. There are however, 
some differences between the healing of a rodent (mice or rats) compared to humans 
[296]. Due to the presence of a panniculosus, rodents tend to heal mainly through 
contraction as opposed to re-epithelialization and granulation tissue formation as in 
humans. Gurtner's group in Stanford University developed a technique that  helps 
circumvent this problem [292]. A silicone splint was fixed onto full thickness skin 
wounds made on mice to prevent the skin from contracting. They reported that the 
technique was accurate and reproducible and that it significantly reduced the 
contraction of the wound. Instead, the wounds healed via granulation tissue formation 
and re-epithelialization. They extended the use of this model to test the effect of 
wound healing using various growth factors and even used it in diabetic mice [297]. 
Other groups have also used similar methods to prevent the contraction in rodent 
models [298,299].  
 
Fig. 46-48 shows the gross appearance of the wounds 7, 11 and 15 days post 
wounding. Wounds treated with scaffolds (both plain and CHITE supplemented) 
showed better wound morphology at Day 7 and Day 11. While the SHAM wound 
appeared raw and open on Day 7 (Fig. 46), the scaffold treated wounds displayed a 
drier wound appearance. The wounds treated with scaffolds enriched with BM-MSCs 
had a wound profile that is flatter too. On day 11 (Fig. 47), the SHAM wound had a 
reddish appearance that bleeds upon touch. The scaffold treated wounds however has 
a pinkish appearance indicative of a stabilized and healing wound. The wounds on 
Day 15 (Fig. 48) on the other hand appeared to be not grossly different from each 
other, indicative that the wound healing response has reached a plateau. When 
measured using ImageJ (Fig. 49) using the criteria shown in Fig. 40, the data reflected 
observations where the scaffold treated conditions showing slightly faster wound 
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closure (non-significant) compared to SHAM treated wounds. The differences in 
wound closure plateau-ed out at around day 11 such that by day 15, no significant 
differences in wound closure between conditions were observed.  
 
 
Fig. 46: Macroscopic observation 7 days after surgery of rats treated with different conditions. 
PSC and SSC treated rats had drier appearing wounds that seemed to have more granulation 
tissue. The wound on SHAM rats appeared largely raw with little granulation tissue (the 





Fig. 47: Macroscopic observation 11 days after surgery of rats treated with different 
conditions. While SHAM treated wounds appeared raw, wounds treated with the scaffold with 




Fig. 48: Macroscopic observation 15 days after surgery of rats treated with different 






Fig. 49: The wound size of the macroscopic images measured and quantified using ImageJ. 
SHAM treated wounds showed slightly slower closure compared to other scaffold treated 
wounds during the earlier stages of wound healing. By day 11 post-op, the differences in 
wound closure has plateaued out and no differences between considitions were observable at 
day 15. Data represent the mean (n=3), and error bars represent standard deviation.  
 
 
5.3.4 Histological re-epithelialization observations 
The samples were excised on day 15 post-op, cut through the midline through the 
sagittal plane of the rat and fresh frozen for cryosectioning. The first section of each 
sample was then stained for pancytokeratin that will give a clear indication of the 
wound's keratinocyte and re-epithelialization status (Fig. 50). The percentage of 
reepithelialization was calculated as shown in Fig. 41. The full granulation tissue 
length perpendicular to the epithelial surface was measured against the length of the 
epithelial gap. The percentage of epithelialized surface was then calculated using the 
formula shown in Fig. 41. The graph in Fig. 51 is a scatter plot of the samples 
measured. A trend that indicates better re-epithelialization in SSC treated samples 





Fig. 50: Compilation of pancytokeratin and α-SMA stainings for the samples. Pancytokeratin 
shows the distance the epithelial tongue travelled for each sample while the boundaries of the 
skin appendages (also stained red with pancytokeratin) indicates the position where the 
granulation tissue is.  α-SMA stains MSCs, endothelial cells and myofibroblasts and can be 
indicative of the extend of myofibroblast and endothelial cell proliferation in the granulation 
tissue of the wound. (n=3) 
 
Fig. 51: Plot of percentage of wound re-epithelialized in each batch of conditions. The data 
suggests a trend of better re-epithelilization in MSC treated samples, PSC and SSC. Each dot 
on the graph represents data from one animal.  
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5.3.5 Granulation tissue assessment 
Picrosirius red staining was then used to visualize the collagen fibers in the 
histological samples. Picrosirius red staining is a histological staining that stains 
collagen red with a yellow background. Under crossed polars, larger diameter 
collagen fibers appear bright yellow/red while the thinner fibers (including type III 
collagen reticular fibers) appear green. The birefringence is highly specific for 
collagen [300,301]. 
 
Fig. 52: Picrosirius red staining of samples. A positive staining under crossed polarized 
microscopy indicates presence of collagen. PSC, SS and SSC samples appears to have more 






Fig. 53: 20X magnified images of the granulation tissue area of each sample. A random 
haphazard deposition of collagen was observed in PSC, SS and SSC samples. (n=3) 
When the samples were stained with picrosirius red, the PSC, SS and SSC samples 
showed more red and yellow staining, indicative of more collagen deposition in the 
granulation tissue (Fig. 52). When looked under higher magnification, it was 
observed that the collagen fibers were mostly randomly orientated and appeared 
relatively sparse with speckles of yellow fibers around (Fig. 53). On the other hand, 
the granulation tissue in SHAM and PS treated samples had a sparse collagen 
deposition suggesting that MSCs and CHITE may help to accelerate the wound 




5.3.6 Human antigen staining to track implanted human BM-MSCs 
Human cells were traced in the 15 days sample using a double antibody staining for 
human Ku80 and mitochondria. Both antibodies are specific for human cells and 
show no cross reaction with rat tissue. A double positive signal staining will indicate 
presence of a human cell. Both PSC as well as SSC samples showed presence of BM-
MSCs in the superficial and deep areas of the wound, indicating integration of 
implanted human BM-MSCs for at least 15 days post-operation (Fig. 54).  
 
Fig. 54: Double staining for human antigens Ku80 and mitochondira in samples implanted 
with human BM-MSCs. Double positive staining indicates the presence of a human cell. 
Human cells were found in both superficial locations as well as deeper locations in the wound 




 5.4 Discussion 
In order to enable the in situ tissue engineering system described in Fig. 38, a method 
to concentrate the cells onto the electrospun scaffold discussed in Chapter 4 was 
devised. The aim was to have a rapid method of concentrating the cells as prolonged 
soaking in aqueous mediums will cause loss of included bioactive cytokines and 
delay treatment times from when the patient is admitted. Filtration of cells is a fast 
and efficient method to allow quick concentration of cells onto the porous 
nanofibrous scaffold.  
 
When tested out, our electrospun mats held up very well to filtration, effectively 
capturing mononucleated cells on their surfaces. The filtered MSC-scaffold construct 
was also easy to remove for application onto the wound site according to laboratory 
observations. A hand-held device to facilitate performing cell filtration in the 
operation room, by the bed-side was hence designed. This would eliminated the need 
for additional devices such as a vacuum pump and allow clinicians to perform a quick 
assembly of the MSC-scaffold tissue modulating construct in situ.   
 
The filtration system works for both freshly isolated autologous bone marrow cells 
and pre-cultured allogenic or xenogenic cells. For fresh bone marrow aspirates, I 
experimented with the best ways to quickly and effectively isolate MSC containing 
mononucleated cells from them. It was determined that RBC lysis to remove 
contaminating erythrocytes from bone marrow aspirates is the most efficient method 
for the best and most consistent yield of MSCs. The details of the investigation can be 
found in Supplementary 6. As a consequence of the result of the study, RBC lysed 
samples were used in the filtration study. However, for the animal studies, due to 
technical difficulties of extracting autologous MSCs from the rats in our animal 




When the MSC-scaffold delivery system was tested in a pilot study involving a 
modified rodent splinted wound model adapted from the work of Gurtner's group 
[292], the initial results were very encouraging. Early wound closure (between day 0 
to day 11) appeared to be faster in treated wounds (either with plain scaffolds or 
CHITE scaffolds, with or without cells) compared to SHAM controls even though the 
data was not significantly different. The gross morphology of the wounds also 
showed drier, more stable looking wounds in the treated wounds compared to the 
SHAM wounds that looked raw even at day 11. However, differences appeared to 
plateau out by day 15. This observation was also seen when the epithelialization of 
the wounds were measured with histological slides from day 15 post-op. Even 
thought all three SSC sample showed complete epithelialization, due to the small 
sample size there was no significant between the re-epithelialization in all five 
conditions.  
 
When the collagen deposition was investigated using picrosirius red staining, it was 
observed that samples with either MSCs or CHITE supplemented showed greater 
staining. This led to the inferment that MSCs and CHITE can contribute to dermal 
reconstruction in a full thickness rat wound. It was also found that implanted MSCs 
were able to persist in the wound site for up to 15 days with cells found both in the 
superficial and deep areas of the wound. This data suggest that the implanted cells 
may have contributed during the earlier phases of wound healing and have 
incorporated themselves into the healing tissue. It is unclear however if the cells will 
be eventually be incorporated into the healed tissue as Wu et al. reported inability to 





In this chapter, a system for concentrating cells via filtration onto the cytokine 
functionalized electrospun scaffold described in Chapter 4 was devised. The resultant 
filtration system is effective in concentrating cells onto the scaffold quickly and this 
allowed the in situ combination of a MSC-scaffold construct during the animal 
studies. No ex vivo culture of the implanted BM-MSCs was carried out. When the in 
situ assembled MSC-scaffold construct was used in a pilot study involving a rodent 
splinted wound model, the treated samples showed better wound gross morphology 
and a trend of faster wound re-epithelialization in the early phases post-wounding. 
Treatment with MSC and/or CHITE scaffold also boosted collagen reconstruction in 
the wound compared. The implanted MSCs were found in both superficial and deep 
areas of the wound 15 days post-implantation, indicating that they integrate at least in 
























Conclusions & Recommendations 
 
6.1 Conclusions 
MSCs play an important role in wound healing. Several ways through which MSCs 
exert its influence have been shown and was discussed in detail in Chapter 2. 
Paracrine secretions of cytokines from MSCs help to shift the wound environment 
from an inflammatory one to a more proliferative and healing one [169,198] and 
stimulate granulation tissue formation [207-210] and angiogenesis[167,187,191]. 
Some studies have also suggested that MSCs can differentiate into skin fibroblasts, 
keratinocytes and endothelial cells though long term persistence of the differentiated 
cells have not been shown [164]. However, the role of MSCs in influencing the ECM 
microenvironment of the wound have not been previously investigated. This is 
despite that MSCs are progenitors for skin dermal fibroblasts that are the major 
incumbent contributors of skin's ECM.  
 
This led me to my first hypothesis that MSCs secrete ECM that modulates wound 
healing. The work in this thesis supported this hypothesis and suggest that MSCs 
under simulated wound conditions can secrete and deposit ECM that are conducive to 
wound healing by promoting proliferation and migration of keratinocytes. In 
comparison to HDF derived ECM, it appears that MSC derived ECM are more 
promoting to keratinocyte motility. Additionally, direct cell-cell interaction between 
MSC and keratinocytes stimulated the deposition of ECM with DEJ characteristics. 
This finding also opens up possibilities of using MSC derived ECM for both acute 




In injured tissue, MSCs have been shown to migrate towards sites of inflammation 
[8] and hypoxia [9]. Others have also shown that the direct application of MSC to the 
wound is also beneficial (summarized in table 4). This led me to my second 
hypothesis that an in situ combination of MSCs with wound modulating cytokines 
will improve wound healing. A scaffold was fabricated to provide transfer support to 
MSCs in order to proof this hypothesis. As a complement, cytokines, CHITE, that can 
potentially boost wound healing was supplemented into the scaffold. An enabling set-
up to that efficiently concentrate MSCs on the fabricated CHITE scaffold was also 
designed. The resultant MSC-CHITE scaffold construct showed promising effects on 
accelerating wound healing and reconstructing the dermis in an acute splinted full-
thickness skin wound model in rats. The hypothesis was only partially addressed as it 
remains to be deciphered if both MSCs and CHITE would be necessary to promote 
wound healing, or either is sufficient.   
 
The main conclusions and achievements are as follows:  
1. It was shown that MSCs are secretors of skin related ECM, Col I, Col III, Col 
IV and fibronectin. Interestingly, the ECM deposition profiles were different 
from ECM secreted by HDFs in response to wound cytokines TGF-β1 and 
TNF-α. The data indicated that ECM produced by MSCs pre-activated with 
TGF- β1 and TNF-α showed an increased ratio of Col III to Col I, 
characteristic of ECM in early wound healing. Functional assays on 
decellularized ECMs deposited by MSCs showed that the ECMs supported 
NHEK proliferation. When pre-activated by TGF-β1, ECM deposited by 
MSCs inhibited NHEK proliferation. Similar behavior was seen in ECM 
secreted by HDFs pre-activated by TGF-β1. ECM deposited by MSC, 
regardless of whether the cells were pre-activated, were strongly stimulating 
to NHEK motility when compared to ECM deposited by HDF. This property 
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may be one of the major factors how MSCs enhance assist wound coverage 
by enhancing keratinocyte motility.  
 
2. I also showed that MSCs when in direct contact with keratinocytes are able to 
produce DEJ-related ECM protein deposition, a pre-requisite for stable skin 
coverage and epithelial maturation. The deposition pattern and location of 
DEJ-related ECM protein was very similar to that deposited when HDFs 
were used instead. Keeping in mind that HDFs are the key producers of 
physiological skin ECM, it is encouraging to see that MSCs are able to 
replace HDFs in coculture with NHEKs. This data also further confirmed 
MSCs' role in secreting ECM that modulates the wound healing process.  
 
3. A bioactive multi-component containing delivery system for MSCs was 
fabricated with the intention to improve skin cell proliferation and viability. 
Five biochemically distinct molecules were blended into an electrospun 
scaffold that was designed to be commercially viable in large scale 
production. The fabricated wound dressing was easy to handle and released 
factors in a controlled manner over 12 hours. Its fast degrading properties 
allowed the scaffold to release space needed for the regenerating tissue. All 
of the five included factors were shown using comprehensive cell assays to 
be bioactive despite relatively harsh processing methods and the dressing was 
also shown to be able to improve the proliferation and maintain the 
proliferative capacity of local skin cells such as NHEKs and fibroblasts.  
 
4. A system for concentrating the cells via filtration onto the fabricated 
bioactive delivery scaffold for our application as also devised. When the in 
situ assembled MSC-scaffold construct was used in a pilot study involving a 
splinted wound model in rats, the therapy containing MSCs and/or CHITE 
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facilitated acceleration of wound re-epithelialization and boosted ECM 
reconstruction in the wound compared to a SHAM or unsupplemented 
scaffold control. This data suggest that the system of MSCs with/or 
supplemented bioactive scaffold can contribute to improving wound healing.  
 
6.2 Recommendations for future work 
1) The mechanism in which MSC deposited ECM increases NHEK motility can to be 
further examined. It is unclear if the increase in motility was due to larger amounts of 
ECM produced by MSCs, the different composition of ECM proteins or that there 
were more growth factors adsorbed and tethered on MSC deposited ECM. 
Elucidating the mechanism of how MSCs enhance NHEK motility will help us better 
understand how different cell types in the wound are concerted to treat a defect and 
with it, devise better treatment options to facilitate tissue regeneration.  
 
2) I showed that the ECM deposited by MSCs are modulated in response to TNF-α 
and TGF-β1 stimulation. By doing a large scale screen different cytokines' influence 
on MSC ECM deposition and its influence on keratinocytes and/or fibroblasts, we 
might be able to prime MSCs prior to using them. This is so that they will have 
maximum efficacy in the wound. The decellularized matrices of primed MSCs may 
also be further processed into tissue engineering scaffolds.  
 
3) While acute wounds were the focus of interest in this work, MSCs have shown a 
lot of positive results in the treatment of chronic wounds. The potent tissue 
modulating construct created in this work may have potential in the treatment of 
chronic wounds. In order to investigate this hypothesis, it would be necessary to do 
an in vivo evaluation of the construct in treating diabetic wound (either db/db mice or 
streptozotocin induced diabetic rats). Inflammation can be introduced to the wounds 
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by inoculating the wound with either Staphylococcus aureus or Pseudomonas 
aeruginosa [302]. 
 
4) The bioactive tissue modulating construct fabricated serves as a dermal 
regeneration template. Keratinocytes however would have to migrate into the wound 
from the wound edges, or an additional epidermal graft needs to be introduced. In 
order to make the system truly one-step in the treatment of large wounds, it would be 
interesting to investigate if combining the created system with ReCell might give 
synergistic results in wound regeneration. ReCell is a standalone system that involves 
taking a small biopsy from the patient and within 30 minutes, isolate and suspend 
skin keratinocytes for spraying onto a wound site [303].  
 
5) In this project, a filtration system for concentrating MSCs onto a electrospun 
membrane was devised. This device can be utilized to enable other cell therapy to be 
administered. Cells of interest may involve insulin-producing beta cells for treatment 
of type I diabetes, stem cells for myocardial infarction or pericytes for treatment of 
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Col I and Col VII staining of NHEK:MSC (4:2) coculture samples counterstained with DAPI. 





Organotypic with HDFs or MSCs seeded in collagen gels and NHEKs seeded on top. 
The figures show the H&E staining of the gels 2 weeks and 3 weeks air-lifting to an 
air-liquid interface. While NHEKs did stratify on MSC seeded collagens, the 
organization of the cells appeared to be disorientated with cells not losing their nuclei 

















(Data courtesy of Miss Lim Sheng Jie Natalie) 
The calculated percentage bioactivity of released hydrocortisone (above) and T3 (below). The 
red letters indicate the percentage release of hydrocortisone and T3 after 24 hours release as 
shown in Fig. 33. Calculation from the weight of scaffolds added into the transwells will give 
us an indication of how much hydrocortisone or T3 is released into the media, from which we 
calculated their concentration. Using the standard curve of hydrocortisone or T3 in the cell 
reporter assay, we were able to corroborate the concentration of bioactive factors present in 
the culture. % Bioactivity = concentration of measured biofactor/concentrated assumed to be 





Morphology of keratinocytes seeded in KBM (above) or FAD (below) media in the presence 
of transwells containing 1) plain scaffolds + CHITE supplements in the media, 2) No scaffold, 






LIVE/DEAD assay of BM-MSCs centrifuged onto electrospun scaffolds and left at room 
temperatures for 45 minutes. (left) Supernatant of culture media was removed and cells were 
relatively dry during the 45 min incubation time. (right) cell culture media was retained and 
cells were wet during the 45 min incubation. The high LIVE cell staining indicates that the 
cells remained viable even when sitting dry on the scaffold for as long as 45 minutes. As the 
proposed cell concentration is filtration immediately before application, it is likely that cells 





In order to enable quick and rapid isolating of BM-MSCs from bone marrow aspirates 
for in situ construction of the MSC-scaffold construct described in Chapters 4 and 5, 
it is necessary to define an efficient and effective method of bone marrow stem cell 
isolation. This work is built upon the research work by Horn et al. (Horn et al. 2008). 
 
Materials and Methods 
Isolation of bone marrow mononucleated cells  
Bone marrow aspirates from pigs due for sacrificing were obtained as gifts from Prof 
James Hui, and Prof James Goh under the NUS Tissue Sharing Programme and 
processed as described below. 
  
Direct Centrifugation 
The bone marrow aspirate was centrifuged at 400g for 10 minutes. The 
supernatant was removed by pipetting and the thin interface between the 
supernatant plasma and the RBC pellet was removed using a 1000 µL pipette. 
The extracted cells were then resuspended in Minimum Essential Medium Eagle 
Alpha (α-MEM medium) (GIBCO, Invitrogen Corporation, USA) and plated 
accordingly. 
 
Ficoll-paque density gradient centrifugation 
The bone marrow aspirates were diluted with Hank's buffered salt solution 
(HBSS) in a ratio of 1 part bone marrow, 2 parts HBSS. The diluted bone 
marrow was then overlaid gently over Histopaque® (Sigma) or Ficoll-paque 
PLUS (GE Healthcare Life Sciences, USA) and centrifuged with slow 
acceleration and brake-off for 30 minutes at 400g. The buffy coat layer between 
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the supernatant plasma and the underlying ficoll layer was extracted and 
resuspended in α-MEM for further plating. The buffy coat was washed by 
centrifugation at 100g for 10 minutes twice. In order to obtain platelets through 
this procedure, the supernatant from all the three centrifugation steps were 
collected and centrifuged at 4000 rpm for 20 minutes. The resultant pellet was 
then resuspended in α-MEM for further plating. 
 
Red Blood Cells (RBC) Lysis 
The bone marrow aspirates were diluted with HBSS in a ratio of 1:1 and mixed 
with gentle pipetting. The diluted bone marrow was then added to at least 3 
times volume of RBC lysis buffer containing ammonium chloride (155 mM), 
sodium bicarbonate (10 mM) and EDTA (11.5 mM) (Sigma). The mixture was 
left on a horizontal shaker at room temperature until there's a distinctive change 
in color of the mixture from dull red to bright red (approximately 10 minutes).  
The mixture was then centrifuged at 180g for 15 minutes and the pellet was 
resuspended in HBSS and washed once before resuspension in α-MEM for 
further plating. Platelets was obtained by centrifuging the supernatant of the first 
centrifuge at 4000 rpm for 20 minutes. The resultant pellet was then resuspended 
in α - MEM for further plating. 
 
Characterization of Bone Marrow Plastic Adherent Mesenchymal Stem Cells 
Colony Forming Units – fibroblasts (CFU-f) 
Approximately 1 million mononucleated cells were seeded per 6 well plate well 
for samples processed by density gradient centrifugation (bone marrow 
processed by other methods were seeded in a volume that corresponded to the 
same volume of bone marrow seeded in the density gradient centrifugation 
sample). The cells were then allowed to adhere and proliferate for 8 days at 37 
°C, 5% CO2. After 8 days, the cells were washed, fixed with 4% 
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paraformaldehyde and stained with 0.5% crystal violet. The number of colonies 
were manually counted and expressed as CFU-f units per mL of bone marrow 
aspirate. In experiments with platelets, platelets of the corresponding volume of 
bone marrow was added in each of the wells approximately 20 minutes after 
seeding of the mononucleated cells. 
 
 
Osteogenic Differentiation and Characterization 
Osteogenesis differentiation of MSCs  was done by plating 2500 cells per 24 
well plate. The cells were allowed to adhere overnight and induction media was 
added the next day. Induction media contained 1 x 10-7 M Dexamethasone, 50 
µM Ascorbic acid, and  10 mM Beta glycerophosphate (all from Sigma) in high 
glucose DMEM with 10% FBS and 1% PS. Media was changed every 3-4 days. 
After 4 weeks in-vitro, the cells were fixed with 4% paraformaldehyde and 
stained with alizarin red stain for calcium deposition. 
 
Adipogenic Differentiation and Characterization 
Adipogenesis differentiation of MSC was done by plating 20, 000 cells per 24 
well plate with low glucose DMEM supplemented with 10% FBS and 1% PS. 
The cells were allowed to grow to confluency for 4 days before addition of 
induction media. The induction media contained 1 µM dexamethasone and 5 
µg/mL insulin in high glucose DMEM with 10% FBS and 1% PS. Media was 
changed every 3-4 days. After 3 weeks, the cells were fixed with 4% 
paraformaldehyde and stained with nile red for lipid droplets. DAPI was also 






Chondrogenic Differentiation and Characterization 
Chondrogenic differentiation of MSCs was induced through aggregate culture. 
Aliquots of 3.0 X 105 cells were centrifuged at 1000 rpm for 5 minutes in 15mL 
polypropylene conical tubes to form pellets, which were then cultured in a 
medium containing high glucose DMEM supplemented with 4mM proline, 50 
mg/mL ascorbic acid, 1% ITS-Premix (Becton-Dickinson), 1mM sodium 
pyruvate, and 0.1 mM dexamethasone for 28 days in the presence or absence of 
10 ng/mL of transforming growth factor- β1 (TGF-β1, R&D Systems, MN 
USA). Medium was changed every 2-3 days. Henceforth, the samples that 
received TGF-β1 treatment will be referred to as treated, while those that did not 
will be referred to as control. After 4 weeks of induction, the cells were fixed 
overnight using 4% paraformaldehyde and embedded in paraffin. The sectioned 








Bone Marrow Mononucleated Cell Isolation  
Direct centrifugation was the easiest and simplest way of isolating components from 
the bone marrow. The process was also much faster than the conventional density 
gradient centrifugation method, taking only 10 minutes (vs. ~1 hour). The extraction 
method was compared in terms of efficacy in extracting MSCs (defined by number of 
CFU-f units formed) with one of the standard methods of extracting MSCs now, 
density gradient centrifugation with a ficoll column. Density centrifugation involves 
overlaying the bone marrow over a ficoll solution that has a density of 1.077 g/mL. 
The bone marrow components were then separated according to their density with red 
blood cells and granulocytes in the bottom densest fraction, followed by the ficoll 
fraction. Above which, in a cloudy fraction (buffy coat) would be the mononucleated 
cell fraction that includes lymphocytes, haematopoietic stem cells and mesenchymal 
stem cells, and the supernatant contains the liquid plasma and platelets (Fig. 43)( 
2011).  
 
A schematic diagram of the mononucleated cell isolation using Ficoll-paque. Cells were 
separated according to their densities with the densest red blood cells at the bottom. 
Mononucleated cells will be found as a buffy coat above clear ficoll-paque. 
   
The CFU-f count is based on the theory that true stem cells have infinite growth 
abilities, and when plated at extremely low densities, will form a homogenous colony 
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after some days of incubation. Each colony is hence taken to be derived from a single 
stem cell. CFU-f has been used extensively in literature as a way to quantify the 
number of true MSCs in an isolated sample (Seeger et al. 2007). The CFU-f forming 
abilities of the cells isolated by direct centrifugation and by density gradient 
centrifugation were compared (Table 6). While the standard protocol recommends 
incubation for 14 days, it was noticed that the colonies grew too large and started 
overlapping after 8 days. Hence, the experiments were stopped on the 8th day and 
colonies with more than 8 cells (instead of 50 cells) were counted. It was actually 
observed that even at 8 days, most of the colonies has more than 30 cells.  
 
The number of CFU-f (/mL of bone marrow) from each pig bone marrow sample. 
 
 Pig 1 Pig 2 Pig 3 
Direct Centrifugation/ mL bone 
marrow 
27 15 51 
Density Gradient Centrifugation/ 
mL bone marrow 




The number of CFU-f formed by density gradient centrifugation was at least 5 times 
more than that with direct centrifugation. This might be attributed to 2 reasons: (1) it 
was almost impossible to accurately identify the mononucleated cell layer in samples 
processed by direct centrifugation as the layer was very thin and immediately above 
the RBC layer, (2) the amount of RBC extracted in the process of extracting the 
mononucleated cell when the sample was processed by density gradient 
centrifugation was a lot. The large quantities of RBC may sterically hinder the 





(Left) The sample after direct centrifugation. The mononucleated cell portion was a very thin 
layer just above the bottom deep red RBC fraction (black arrow). (Right) A photograph of the 
cells plated for CFU-f shows large quantities of RBCs (identified by their bright red colour). 
 
Density gradient centrifugation allowed a more efficient  isolation of BM-MSCs. It 
was then found in literature that the isolation of mononucleated cells though RBC 
lysis was able to extract slightly more CFU-f per  mL of bone marrow with larger 
colony diameters with no adverse effect on cell morphology and differentiation 
properties (Horn et al. 2008). Indeed, when the CFU-f forming abilities of cells 
isolated by density gradient centrifugation and  RBC lysis were compared, the 30 
minute RBC lysis procedure gave a fairly consistent number of 399 ± 54 colony 
forming units (CFU-f) per mL of bone marrow aspirate compared to ficoll-paque 
density gradient centrifugation (CFU-f no. = 201 ± 225, p = 0.015). This indicated 
that RBC lysis procedure is a more reliable and efficient method to isolate BM-
MSCs.  
 
The number of CFU-f units formed per mL of bone marrow for samples that were processed 
by density gradient centrifugation and by RBC lysis. The samples processed by RBC lysis 
showed greater consistency between pigs and the number of CFU-f units formed for each pig 
also increased for most of the samples. The numbers below each column indicated the serial 
number of the pig. 
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Validation that isolated cells contained a fraction of MSCs 
The isolated porcine mononucleated cells were cultured for 2-3 more passages on 
TCP in order to purify the obtained MSCs. The MSCs at passage 2-3 were then 
subjected to in vitro differentiation protocols to determine if they have potential to 
differentiate into the three lineages of mesenchymal stem cells as defined by the 
International Society for Cellular Therapy (Horwitz et al. 2005). It was observed that 
the obtained cells were able to differentiate into the chondrogenic, osteogenic and 
adipogenic lineages, indicating that the isolated cells fulfilled the requirements of a 
mesenchymal stem cell. 
 
As it was not possible to obtain suitable antibodies for testing pig MSC markers with 
flow cytometry, we sufficed with the cells that we obtained fulfilling two of the three 
MSC criterion.   
 







In this supplementary, I hope to bridge the gap between bench top research and the 
clinics by designing something that would enable the use of autologous bone marrow 
derived stem cells in the bedside treatment of wounds. Bone marrow derived MSC is 
in extremely low numbers in the bone marrow. Caplan et. al. reported approximately 
330 MSCs per mL of bone marrow aspirate (Lennon and Caplan 2006). Hence, it is 
of great importance for us to ensure maximum recover of the cells for our autologous 
treatment option.  
 
Currently, isolating bone marrow mononucleated cells for cell therapy via density 
gradient centrifugation using ficoll-paque is common practice in the clinics (Rho et 
al. 2009). It is however a method that requires specific centrifuges with free rotating 
buckets and a brake-off function. The process of isolating the cells is also quite long: 
up to 60-90 minutes. It is also technically tricky to obtain good yield of MSC-rich 
mononucleated cell fraction without proper training. In fact, companies like Stem 
Cell Technologies even have products to help make it easier to overlay bone marrow 
aspirations onto the ficoll-paque and obtain a cleaner, RBC-free mononucleated cell 
fraction .  
 
Using RBC lysis as an alternative method to isolate bone marrow derived 
mononucleated cells, is a relatively new method introduced by Horn et. al. in 2008 
(Horn et al. 2008). My data suggested that RBC lysis was able to give extremely 
consistent quality of MSCs in a very controlled environment where the donor pigs 
were of identical age, strain, source and the bone marrow aspirate was obtained by 
the same surgeon. I also showed that the cells isolated using the RBC lysis method 
retained their multilineage differentiation potential. This data is consistent with what 
Peterbauer-Scherb et. al. showed: that RBC lysis as a bone marrow stem cell isolation 
method does not affect the chondrogenic differentiation capabilities of the isolated 
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cells (Peterbauer-Scherb et al. 2010). Their cells have similar potential for generating 
cartilaginous tissue in vitro compared to both dextran sedimentation and density 
gradient centrifugation. Agata on the other hand reported that RBC lysis method 
provided for greater number of cells that are more potent for osteogenic 
differentiation compared to density gradient centrifugation (Agata 2013). Al Battah 
et. al. suggested that the method of isolation may depend on the eventual targeted 
mature cell type we hope to obtain (Al Battah et al. 2011). It may be that application 
of a particular subset of MSCs would best facilitate wound healing. For my studies, I 
felt that obtaining as much MSCs as possible is of paramount importance and RBC 
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